FORM 10-K
FOR ANNUAL AND TRANSITION REPORTS PURSUANT TO
SECTIONS 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
(Mark One)
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the fiscal year ended December 31, 2001
OR
[_] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES
EXCHANGE ACT OF 1934
Commission File No. 0-15327
CYTRX CORPORATION
(Exact name of Registrant as specified in its charter)
Delaware 58-1642740 (State or other (I.R.S. jurisdiction of Employer Identification incorporation or No.) organization) 154 Technology Parkway Suite 200 Norcross, Georgia 30092 30092 (Address of principal (Zip Code) executive offices) |
Registrant's telephone number, including area code: (770) 368-9500
Securities registered pursuant to Section l2(b) of the Act:
None
Securities registered pursuant to Section 12(g) of the Act:
Common Stock, $.001 par value per share
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and (2) has been subject to such filing requirements for the past 90 days. YES [X] NO [_]
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the Registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [X]
The aggregate market value of the Registrant's common stock held by non-affiliates on March 26, 2002 was approximately $9.3 million. On March 26, 2002, there were 11,564,779 shares of the Registrant's common stock outstanding, exclusive of treasury shares.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the CytRx Corporation Proxy Statement for the 2002 Annual Meeting of Stockholders (the "Proxy Statement") are incorporated by reference into Part III.
"SAFE HABOR" STATEMENT UNDER THE
PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
From time to time, we make oral and written statements that may constitute "forward looking statements" (rather than historical facts) as defined in the Private Securities Litigation Reform Act of 1995 or by the Securities and Exchange Commission (the "SEC") in its rules, regulations and releases, including Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E or the Securities Exchange Act of 1934, as amended. We desire to take advantage of the "safe harbor" provisions in the Private Securities Litigation Reform Act of 1995 for forward looking statements made from time to time, including, but not limited to, the forward looking statements made in this Annual Report on Form 10-K (the "Annual Report"), as well as those made in other filings with the SEC.
Forward looking statements can be identified by our use of forward looking terminology such as "may", "will", "expect", "anticipate", "estimate", "believe", "continue", or other similar words. Such forward looking statements are based on our management's current plans and expectations and are subject to risks, uncertainties and changes in plans that could cause actual results to differ materially from those described in the forward looking statements. In the preparation of this Annual Report, where such forward looking statements appear, we have sought to accompany such statements with meaningful cautionary statements identifying important factors that could cause actual results to differ materially from those described in the forward looking statements, and we have described many such items under "Risk Factors" set forth in "Management's Discussion and Analysis of Financial Condition and Results of Operations" below.
We do not have, and expressly disclaim, any obligation to release publicly any updates or any changes in our expectations or any changes in events, conditions or circumstances on which any forward looking statement is based.
PART I
Item 1. Business
General
We are a Delaware corporation, which was incorporated in 1985, and are engaged in the development and commercialization of pharmaceutical products. Our current research and development activities include FLOCOR, an intravenous agent for treatment of sickle cell disease and other acute vaso-occlusive disorders, and TranzFect, a delivery technology for DNA-based vaccines. We also have a research pipeline with opportunities in the areas of muscular dystrophy, cancer, spinal cord injury, vaccine delivery and gene therapy. See "Product Development" below.
Certain financial information concerning the industry segments in which the Company operates can be found in Note 14 to the Company's Consolidated Financial Statements.
Recent Developments
On February 11, 2002 the Company entered into an Agreement and Plan of Merger whereby CytRx will acquire Global Genomics Capital, Inc. ("GGC"), a privately held genomics holding company, pursuant to the merger of GGC Merger Corporation, a wholly-owned subsidiary of CytRx, with and into GGC. GGC will continue as a wholly-owned subsidiary of CytRx after the merger. The terms of the merger provide for CytRx to acquire all outstanding shares and rights to acquire capital stock of GGC in return for the issuance or reservation for issuance of a maximum of 9,962,881 shares of CytRx Common Stock. The closing of the transaction is anticipated in the second quarter of 2002, and is contingent upon approval by the shareholders of each company and other customary closing conditions. Subject to shareholder approval, CytRx will change its name to Global Genomics, Inc. upon completion of the merger.
In February 2002, the Company terminated the operations of its Spectrum Recruitment Research recruiting services segment and assigned the rights to use the Spectrum tradenames to a consulting firm comprised of former Cytrx employees. See Note 16 to the Company's Consolidated Financial Statements.
Product Development
Therapeutic Copolymer Programs
General. Our primary focus is on CRL-5861 (purified poloxamer 188), a novel, intra-vascular agent with pharmacological properties that can be characterized as rheologic, cytoprotective and anti-adhesive/anti-thrombotic. CRL-5861 is an intravenous solution that has the unique property of improving micro-vascular blood flow. Extensive preclinical and clinical studies suggest CRL-5861 may be of significant benefit in acute ischemic vascular disorders such as stroke, heart attack, and vaso-occlusive crisis of sickle cell disease. CRL-5861 may also provide benefit in cancer when used in combination with radiation or cytotoxic drugs. Through its effect on increasing blood flow, CRL-5861 is thought to (1) increase delivery of cytotoxic drugs to ischemic portions of tumors, and (2) increase oxygen delivery, thus increasing the sensitivity of tumor cells to drug and radiation therapy.
The safety profile of CRL-5861 is well established. It has been investigated in over 17 clinical studies representing administration to approximately 4,000 patients and healthy volunteers.
Sickle Cell Disease. We believe CRL-5861 has significant potential in treating a variety of vascular-occlusive diseases, including sickle cell disease, spinal cord compression injury, muscular dystrophy and delivery of anti-cancer agents. For purposes of our sickle cell disease development program, we refer to CRL-5861 as "FLOCOR".
Sickle cell disease is a devastating disorder originating from an inherited abnormality of hemoglobin, the oxygen-carrying molecule in red blood cells. Under conditions of low blood oxygen, which is generally caused by dehydration or stress, the sickle cell victim's hemoglobin becomes rigid causing red blood cells to become rough, sticky and irregularly shaped, often looking like sickles, which gives the disease its name. Estimates place the number of persons suffering from sickle cell anemia in the U.S. at about 72,000, or roughly one in 400 African-Americans. It is also estimated that complications from sickle cell disease result in healthcare expenditures of $1.0 to $1.5 billion annually in the U.S.
The most common problem sickle cell patients face is episodic pain (also referred to as vaso-occlusive crisis, or VOC). These episodes can last anywhere from days to weeks, and can vary significantly in their severity. The deformed sickle cells cannot easily flow through the smaller blood vessels of the body and tend to clump together, forming occlusions which impede blood flow. The occlusions deprive tissues of vital oxygen that can result in tissue death, inflammation and intense throbbing pain. Aside from causing considerable pain and suffering, these crisis episodes slowly destroy vital organs as they are deprived of oxygen. As a result, the life expectancy of sickle cell victims is about twenty years shorter than those without the disease. Patients suffering from sickle cell disease may experience several crisis episodes each year. Hospitalization is required when pain becomes too much to bear. There are about 75,000 hospital admissions annually to treat sickle cell patients undergoing acute vascular-occlusive crisis caused by the disease. On average, these patients require in-patient treatment for four to seven days. Currently there is no disease modifying treatment for acute crisis of sickle cell disease and treatment is limited to narcotics, fluids, and bed rest.
In sickle cell disease, the application of FLOCOR can best be described as an intravenous blood "lubricant". FLOCOR's unique surface-active properties decrease blood viscosity and enable the rigid sickled cells to become more flexible, thus allowing easier passage of blood cells through narrow blood vessels. We believe FLOCOR can shorten the episodes of vaso-occlusive crises and, most importantly, preserve organ function.
On December 21, 1999, we reported results from a Phase III clinical study of FLOCOR for treatment of acute sickle cell crisis. Although the study did not demonstrate statistical significance in the primary endpoint, statistically significant and clinically important benefits associated with FLOCOR were observed in certain subgroups. In addition, among the entire patient population, treatment with FLOCOR resulted in a statistically significant increase in the percentage of patients achieving resolution of their crisis. The Phase III study also demonstrated that FLOCOR is well tolerated. Based on the encouraging efficacy results and a good safety profile, our independent Data and Safety Monitoring Board (DSMB) and other thought leaders in the area of sickle cell disease recommended that we continue with clinical development of FLOCOR in sickle cell disease. We presented the results of the Phase III trial at the 24th Annual Meeting of the National Sickle Cell Disease Program in Philadelphia on April 12, 2000, and published the results in the Journal of the American Medical Association (2001, vol. 286).
Based on our conversations with the United States Food and Drug Administration (FDA), it is likely that either two small additional pivotal trials or one large trial will be required for FLOCOR's approval, along with one to two additional safety studies. We have collaborated with a consortium of pediatric hematology centers, led by Johns Hopkins University School of Medicine, to design a follow-up Phase III trial to further investigate FLOCOR in children with sickle cell crisis. Johns Hopkins University School of Medicine, in cooperation with the Maryland Medical Research Institute, has submitted grant applications to the National Heart, Lung and Blood Institute of the National Institutes of Health for financial support of the trial. We believe there is a reasonable possibility of obtaining government funding to support one or more of the remaining trials, which will minimize, but not eliminate our expenditures. If we are successful, we would anticipate earliest funding approval in the third quarter of 2002. The additional studies would take approximately three years to complete following patient enrollment, which might begin in the first quarter of 2003.
FLOCOR has been granted "Orphan Drug" designation by the FDA for the treatment of sickle cell crisis. The Orphan Drug Act of 1983, as amended, provides incentive to drug manufacturers to develop drugs for the treatment of rare diseases (for example diseases that affect less than 200,000 individuals in the United States, or diseases that affect more than 200,000 individuals in the United States where the sponsor does not reasonably anticipate that its product will become profitable). As a result of the designation of FLOCOR as an Orphan Drug, if we are the first manufacturer to obtain FDA approval to market FLOCOR for treatment of sickle cell crisis, we will obtain a seven-year period of marketing exclusivity beginning from the date of FLOCOR's approval. During this period, the FDA may not approve the same drug for the same use from another sponsor.
Cancer--Cancer is the second leading cause of death in the United States. Chemotherapy and/or radiation treatments have highly variable results and improvements to these standard regimens are drastically needed.
CRL-5861 possesses properties that appear to increase blood flow to poorly perfused areas of tumors, thus allowing chemotherapeutic agents to treat such areas more effectively. By increasing blood flow, the tumors become more active and sensitive to chemotherapy or radiation. Early preclinical studies have shown promising results of CRL-5861's activity.
Muscular Dystrophy--Duchenne muscular dystrophy (DMD) is an inherited disorder caused by an abnormal gene for a muscle protein known as dystrophin. Muscles deficient in dystrophin break down under normal muscular activity and the disease results in progressive muscle wasting, paralysis, and death often by age 20. There is no treatment that is effective in preventing the progressive muscle destruction of this devastating disorder. Several years ago, we began collaborating with researchers at the University of Cincinnati Medical Center to study CRL-5861 in the treatment of Muscular Dystrophy. Recently, the collaboration was awarded a research grant from the Muscular Dystrophy Association for further studies in animal models. If these laboratory studies suggest CRL-5861 can protect dystrophin deficient mice, it may work similarly in humans with DMD.
Spinal Cord Injury--Traumatic spinal cord damage is one of the most devastating injuries imaginable, and unfortunately occurs primarily in young people, often resulting in complete paralysis. Researchers believe that a significant portion of spinal cord damage results from a secondary progression of damage after the initial injury. This secondary injury results from membrane injury to nerve cells, causing them to lose function over time.
We are currently testing CRL-5861 for its ability to interact with damaged nerve membranes in such a way as to "seal" the damage and restore membrane integrity. If successful, this treatment could limit the progression of secondary, post-injury damage, thereby maintaining or restoring spinal cord function. Based on the successful outcome of these studies, we believe we can proceed very quickly with the clinical development of this agent since the program will benefit from the existing safety and manufacturing capabilities already in place for our FLOCOR program.
Vaccine Enhancement and Gene Therapy
DNA Vaccines & Gene Therapy--Gene therapy and/or gene based vaccines are mediated through the delivery of DNA containing selected genes into cells by a process known as transfection. We refer to our gene delivery technology as TranzFect. A common class of materials used to enhance the transfection process are known as cationic lipids. This type of lipid can associate with and alter the integrity of a cell membrane, thus increasing the uptake of the complexed DNA. Unfortunately, cationic lipids are toxic to cells and are readily metabolized. Thus the effect of these agents in transfection protocols is not readily reproducible when used in vivo.
We have identified a series of non-ionic block copolymers known as poloxamers that share several physico-chemical traits with the cationic lipids in that they associate with DNA and cell membranes. However, the block copolymers are significantly less toxic than the cationic lipids and are not metabolized in vivo. In addition, the poloxamer family of non-ionic block copolymers have a significant history of being safely used in a wide variety of oral, injectable, and topical pharmaceutical products. Importantly, a poloxamer known as CRL-1005 which is among the most active in transfection protocols and is adjuvant active, has been studied in a Phase I clinical trial. In that trial, CRL-1005 was well tolerated at doses significantly higher than those anticipated to be useful in gene therapy or DNA vaccine studies.
In addition to the ability of poloxamers to enhance transfection, these compounds have significant immuno-adjuvant activity. Accordingly, we believe that an optimal application for this technology may be in the field of DNA vaccines. We believe that in this application, the activity of poloxamers will be two-fold. First, the poloxamers will act as delivery/transfection agents to facilitate the intracellular delivery and protection of the DNA from enzymatic digestion. Second the poloxamer will act as an immuno-adjuvant. Since the poloxamer is not metabolized and has surface active properties, it is likely to remain on the surface of the transfected cell awaiting expression of the gene. When the gene product is excreted from the cell, the poloxamer is likely to
associate with the antigen and exert immuno-adjuvant actions. Numerous preclinical and clinical studies have demonstrated that conventional vaccines adjuvanted with poloxamers are well tolerated and result in significantly enhanced antibody and cellular immune responses.
A large majority of CytRx's revenus over the past two years has been generated from license fees paid to CytRx with respect to its TranzFect technology.
Merck License--In November 2000, we entered into an exclusive, worldwide license agreement with Merck & Co., Inc. whereby we granted Merck the right to use our TranzFect technology in DNA-based vaccines targeted to four infectious diseases, one of which is HIV.
In November 2000 Merck paid us a signature payment of $2 million and in February 2002, Merck paid us an additional $1 million milestone fee related to the commencement by Merck of the first FDA Phase I Study for the first product incorporating TranzFect designed for the prevention and treatment of HIV. Merck will also pay us up to $3 million in $1 million increments within 30 days of the occurrence of each of the following: (1) the commencement by Merck of the earlier of the first FDA Phase IIb Study or Phase III Study for such HIV product; (2) the filing by Merck of the first U.S. Public Health Service Act Product License Application in one of the countries mentioned below for such HIV product; and (3) notification from a regulatory authority in the United States, Canada, France, Germany, Italy, Spain, the United Kingdom, or Japan that all approvals for the marketing of such HIV product, including pricing approvals, have been granted. Merck will also pay us an annual fee of $50,000 the first year, $75,000 the second year, and $100,000 the third year and each additional year thereafter until Merck receives notification from a regulatory authority as mentioned above.
For the products incorporating TranzFect targeting the other diseases, Merck
will pay us milestone payments of up to $2,850,000 in the following increments:
(1) $100,000 for the commencement by Merck of the first FDA Phase I Study; (2)
$250,000 for the commencement by Merck of the earlier of the first FDA Phase
IIb Study or Phase III Study; (3) $500,000 for the filing by Merck of the first
U.S. Public Health Service Act Product License Application in one of the
countries mentioned below; and (4) $2 million for notification from a
regulatory authority in the United States, Canada, France, Germany, Italy,
Spain, the United Kingdom, or Japan that all approvals for the marketing of
such product, including pricing approvals, have been granted.
Merck also will pay to us royalties of between 2% and 4%, on a country-by-country basis, based on net sales. Merck will pay an additional 1% royalty on net sales if certain conditions are met regarding patent protection and Merck's competitive position. The royalty payments are subject to certain reductions.
This agreement remains effective unless terminated according to its terms by either party or until the expiration of all royalty obligations thereunder. Merck may terminate this agreement at any time in its sole discretion by giving 90 days written notice. Upon termination by Merck, the rights and obligations under the agreement, including any licenses and payment obligations not yet due, also terminate. The agreement may also be terminated for cause by either party. All amounts paid to us are non-refundable and require no additional efforts on our part.
Restrictions in the Merck license prevent us from disclosing certain of its terms, including some of the specific disease targets covered. We have applied with the SEC for and have received confidential treatment for certain portions of the agreement, which have been omitted from the exhibit filed with the SEC.
Vical License--On December 7, 2001, CytRx entered into a license agreement with
Vical Incorporated granting Vical exclusive, worldwide rights to use or
sublicense CytRx's TranzFect poloxamer technology to enhance viral or non-viral
delivery of polynucleotides (such as DNA and RNA) in all preventive and
therapeutic human and animal health applications, except for (1) four
infectious disease vaccine targets previously licensed by CytRx to Merck, and
(2) DNA vaccines or therapeutics based on prostate-specific membrane antigen
(PSMA). In addition, the Vical license permits Vical to use TranzFect poloxamer
technology to enhance the delivery of proteins in prime-boost vaccine
applications that involve the use of polynucleotides.
Under the Vical license, CytRx received an up-front payment of $3,750,000 and has the potential to receive milestone and royalty payments in the future based on criteria described in the agreement. All amounts paid to us are non-refundable upon termination and require no additional effort on our part. Restrictions in the Vical license
prevent us from disclosing certain of its terms, including some of the specific terms of the potential milestone and royalty payments. We have applied with the SEC for confidential treatment for certain portions of the agreement that we have omitted from the exhibit filed with the SEC.
Conventional Vaccines--As part of our TranzFect program, we have developed a library of compounds, many of which have been shown to enhance the activity of conventional vaccines. We refer to this program as Optivax. Other companies are currently evaluating the Optivax compounds for possible license.
Other Product Development Efforts
Food Animal Growth Promotant--The United States Food and Drug Administration has expressed a growing concern about the use of low level antibiotics in animal feed and the possibility of resultant antibiotic resistance in human pathogens. Pending regulations at the FDA could suspend farmers' use of any antibiotics found to promote the spread of resistant human pathogens. In experimental studies, our compound, CRL-8761, has been shown to have a consistent effect to improve the rate of weight gain and feed efficiency in well-controlled studies in poultry and swine. CRL-8761 consistently provides the same growth performance benefits as antibiotics but, since it has no antibiotic activity, it is free from human health concerns over the use of antibiotics.
In February 2001, we entered into a license agreement with Ivy Animal Health, Inc. under which we granted Ivy a worldwide exclusive license to CRL-8761. As part of the license, we received a nominal upfront payment, and will receive a milestone fee upon regulatory approval in the United States and a future royalty equal to 5% of net sales.
Research and Development Expenditures
Expenditures for research and development activities related to continuing operations were $1.8 million, $2.0 million and $12.8 million during the years ended December 31, 2001, 2000 and 1999, respectively.
Manufacturing
We require three suppliers of materials or services to manufacture CRL-5861;
(i) a supplier of the raw drug substance, (ii) a supplier of the purified drug
which is refined from the raw drug substance and (iii) a manufacturer who can
formulate and sterile fill the purified drug substance into the finished drug
product. The raw drug substance is currently widely available at commercial
scales from numerous manufacturers. We have not entered into a formal agreement
with any supplier for the raw drug substance because of its wide availability.
In August 1999, we entered into a long-term commercial supply contract with
Organichem, Corp., located in Rennselaer, New York for production of the
purified drug substance. There can be no assurance that our relationship with
such supplier will continue or that we will be able to obtain additional
purified drug substance if our current supply is inadequate. Such inability to
obtain additional purified drug substance in amounts and at prices acceptable
to the Company could have a material adverse effect on our business. To meet
the need for manufacture of our finished drug product, we have entered into a
supply agreement with the Hospital Products Division of Abbott Laboratories.
Our inability to maintain such relationship on terms acceptable to us could
have a material adverse effect on our business.
If we modify our manufacturing process or change the source or location of product supply, regulatory authorities will require us to demonstrate that the material produced from the modified or new process or facility is equivalent to the material used in our clinical trials. Further, any manufacturing facility and the quality control and manufacturing procedures used by us for the commercial supply of a product must comply with applicable Occupational Safety and Health Administration, Environmental Protection Agency, and FDA standards, including Good Manufacturing Practice regulations. See "Government Regulation" below.
Patents and Proprietary Technology
We actively seek patent protection for our technologies, processes, uses, and ongoing improvements and consider our patents and other intellectual property to be critical to our business.
We continually evaluate the patentability of new inventions and improvements developed by our employees and collaborators. Whenever appropriate, we will endeavor to file United States and international patent applications to protect these new inventions and improvements. However, there can be no assurance that any of the current pending patent applications or any new patent applications that may be filed will ever be issued in the United States or any other country.
We also attempt to protect our proprietary products, processes and other information by relying on trade secrets and non-disclosure agreements with our employees, consultants and certain other persons who have access to such products, processes and information. Under the agreements, all inventions conceived by employees are our exclusive property. Nevertheless, there can be no assurance that these agreements will afford significant protection against misappropriation or unauthorized disclosure of our trade secrets and confidential information.
We believe we have worldwide comprehensive intellectual property covering the use of poloxamers in a number of therapeutic areas. We have patents claiming broad areas of the use of these compounds currently pending or issued in Canada, Japan, South Korea, the European Patent Office and the United States. On November 23, 1999 the U.S. Patent Office issued patent No. 5,990,241 "Polyoxypropylene/Polyoxyethylene Copolymers With Improved Biological Activity" to us. We believe the issue of this patent provides important exclusivity since it contains composition of matter claims for purified poloxamers used in our products and technologies, including purified poloxamer 188, the active ingredient in CRL-5861. This patent will expire in 2017. We also own a comprehensive group of patents that broadly claim the use of poloxamers as vaccine adjuvants that will provide additional coverage for DNA vaccines.
Competition
Many companies, including large pharmaceutical, chemical and biotechnology firms with financial resources, research and development staffs, and facilities that are substantially greater than ours, are engaged in the research and development of pharmaceutical products that could compete with products under development by us. The industry is characterized by rapid technological advances and competitors may develop their products more rapidly and/or such products may be more effective than those under development by us or our licensees and corporate partners.
Government Regulation
The marketing of pharmaceutical products requires the approval of the FDA and comparable regulatory authorities in foreign countries. The FDA has established guidelines and safety standards which apply to the pre-clinical evaluation, clinical testing, manufacture and marketing of pharmaceutical products. The process of obtaining FDA approval for a new therapeutic product (drug) generally takes several years and involves the expenditure of substantial resources. The steps required before such a product can be produced and marketed for human use in the United States include preclinical studies in animal models, the filing of an Investigational New Drug ("IND") application, human clinical trials and the submission and approval of a New Drug Application ("NDA"). The NDA involves considerable data collection, verification and analysis, as well as the preparation of summaries of the manufacturing and testing processes, preclinical studies, and clinical trials. The FDA must approve the NDA before the drug may be marketed. There can be no assurance that we will be able to obtain the required FDA approvals for any of our products.
The manufacturing facilities and processes for our products, whether manufactured directly by us or by a third party, will be subject to rigorous regulation, including the need to comply with Federal Good Manufacturing Practice regulations. We are also subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Nuclear Energy and Radiation Control Act, the Toxic Substance Control Act and the Resource Conservation and Recovery Act.
Employees
As of December 31, 2001, we had four full-time employees and one part-time employee.
Item 2. Properties
We currently lease administrative office space at 154 Technology Parkway, Norcross, Georgia. These facilities are in satisfactory condition and suitable for our purposes and present operations. We also use contract lab facilities for research and development purposes.
Item 3. Legal Proceedings
We are not a party to any material litigation. We are occasionally involved in other claims arising out of our operations in the normal course of business, none of which are expected, individually or in the aggregate, to have a material adverse affect on us.
Item 4. Submission of Matters to a Vote of Security Holders
None.
PART II
Item 5. Market for Registrant's Common Equity and Related Stockholder Matters
Our Common Stock is traded on the Nasdaq National Market under the symbol CYTR. The following table sets forth the high and low sale prices for our Common Stock for the periods indicated as reported by Nasdaq. Such prices represent prices between dealers without adjustment for retail mark-ups, mark-downs, or commissions and may not necessarily represent actual transactions.
High Low ---- --- COMMON STOCK: 2002 January 1 to March 26. 1.00 .56 2001 Fourth Quarter........ .94 .45 Third Quarter......... 1.12 .61 Second Quarter........ 1.35 .79 First Quarter......... 1.22 .75 2000 Fourth Quarter........ 1.56 .47 Third Quarter......... 1.63 .81 Second Quarter........ 2.88 .81 First Quarter......... 6.44 .91 |
On March 26, 2002, the closing price of our Common Stock as reported on The Nasdaq Stock Market, was $0.86 and there were approximately 1,100 holders of record of our Company's Common Stock. The number of record holders does not reflect the number of beneficial owners of our Common Stock for whom shares are held by brokerage firms and other institutions. We have not paid any dividends since our inception and do not contemplate payment of dividends in the foreseeable future.
Item 6. Selected Financial Data
2001 2000 1999 1998 1997 ---------- ----------- ------------ ----------- ----------- Statement of Operations Data: Revenues: Service revenues......................... $ 101,463 $ 451,031 $ 322,536 $ 350,789 $ 422,039 License fees............................. 3,751,000 2,000,000 -- -- -- Interest and other income................ 546,947 876,827 1,068,924 1,762,747 1,381,306 ---------- ----------- ------------ ----------- ----------- Total revenues............................ 4,399,410 3,327,858 1,391,460 2,113,536 1,803,345 ========== =========== ============ =========== =========== Loss from continuing operations........... (931,341) (1,147,457) (15,269,918) (7,737,296) (4,618,867) Income (loss) from discontinued operations -- 799,355 240,627 2,943,937 (1,434,125) Extraordinary item........................ -- -- -- (325,120) -- ---------- ----------- ------------ ----------- ----------- Net loss.................................. $ (931,341) $ (348,102) $(15,029,291) $(5,118,479) $(6,052,992) ========== =========== ============ =========== =========== Basic and diluted loss per common share: Loss from continuing operations.......... $ (0.09) $ (0.12) $ (1.99) $ (1.01) $ (0.62) Income (loss) from discontinued operations............................. -- 0.08 0.03 0.38 (0.20) Extraordinary item....................... -- -- -- (0.04) -- ---------- ----------- ------------ ----------- ----------- Net loss................................. $ (0.09) $ (0.04) $ (1.96) $ (0.67) $ (0.82) ========== =========== ============ =========== =========== Balance Sheet Data: Total assets.............................. $7,610,596 $ 6,859,238 $ 6,128,063 $16,641,568 $24,905,995 Long-term debt............................ -- -- 650,000 -- -- Other long-term liabilities............... -- -- 1,693,638 -- -- Convertible debentures.................... -- -- -- -- 2,000,000 Total stockholders' equity................ 6,582,751 5,618,814 1,032,688 14,688,548 19,248,395 |
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations
This discussion includes "forward looking" statements that reflect our current views with respect to future events and financial performance. Investors should be aware that actual results may differ materially from our expressed expectations because of risks and uncertainties inherent in future events, particularly those risks identified under "Risk Factors" set forth below, and should not unduly rely on these forward looking statements. We undertake no duty to update the information in this discussion if any forward looking statement later turns out to be inaccurate.
The following should be read in conjunction with Selected Financial Data and the audited consolidated financial statements of CytRx included in this report.
Critical Accounting Policies and Estimates
Management's discussion and analysis of its financial condition and results of operation are based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities.
On an on-going basis, management evaluates its estimates, including those related to revenue recognition, bad debts, accrued liabilities and certain expenses. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions.
Our significant accounting policies are summarized in Note 2 to the financial statements. We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of our consolidated financial statements.
Revenue Recognition
Service revenues are recognized at the time services are rendered. CytRx does not require collateral or other securities for sales made on credit. Revenues from collaborative research arrangements and grants are generally recorded as the related costs are incurred. The costs incurred under such arrangements are recorded as research and development expense and approximated the revenues reported in the accompanying statements of operations. Non-refundable license fee revenue is recognized upon receipt when no continuing involvement of CytRx is required and payment of the license fee represents the culmination of the earnings process. Non-refundable license fees received subject to future performance by CytRx or that are credited against future payments due to CytRx are deferred until services are performed, future payments are received or termination of the agreement, whichever is earlier.
Stock-based Compensation
CytRx grants stock options and warrants for a fixed number of shares to key employees and directors with an exercise price equal to the fair market value of the shares at the date of grant. CytRx accounts for stock option grants and warrants in accordance with APB Opinion No. 25, Accounting for Stock Issued to Employees and related interpretations, and, accordingly, recognizes no compensation expense for the stock option grants and warrants for which the terms are fixed. For stock option grants and warrants which vest based on certain corporate performance criteria, compensation expense is recognized to the extent that the quoted market price per share exceeds the exercise price on the date such criteria are achieved or are probable. At each reporting period end, CytRx must estimate the probability of the criteria specified in the stock based awards being met. Different assumptions in assessing this probability could result in additional compensation expense being recognized. In October 1995, the FASB issued Statement of Financial Accounting Standards No. 123, Accounting for Stock-based Compensation, which provides an alternative to APB 25 in accounting for stock-based compensation issued to employees. However, CytRx has continued to account for stock-based compensation in accordance with APB 25 (See Note 8 to financial statements). CytRx has also granted stock options and warrants to certain consultants and other third parties. Stock options and warrants granted to consultants and other third parties are accounted for in accordance with Emerging Issues Task Force No. 96-18, Accounting for Equity Instruments That Are Issued for Sales of Goods and Services to Other Than Employees, and are valued at the fair market value of the options and warrants granted or the services received, whichever is more reliably measurable. Expense is recognized in the period in which a performance commitment exists or the period in which the services are received, whichever is earlier.
Liquidity and Capital Resources
At December 31, 2001, we had cash and cash equivalents of $5.3 million and net assets of $6.6 million, compared to $3.8 million and $5.6 million, respectively, at December 31, 2000. Working capital totaled $4.4 million at December 31, 2001, compared to $2.7 million at December 31, 2000.
On December 7, 2001, CytRx entered into a license agreement with Vical Incorporated granting Vical exclusive, worldwide rights to use or sublicense CytRx's TranzFect poloxamer technology to enhance viral or non-viral delivery of polynucleotides (such as DNA and RNA) in all preventive and therapeutic human and animal health applications, except for (1) four infectious disease vaccine targets previously licensed by CytRx to Merck, and (2) DNA vaccines or therapeutics based on prostate-specific membrane antigen (PSMA). In addition, the Vical license permits Vical to use TranzFect poloxamer technology to enhance the delivery of proteins in prime-boost
vaccine applications that involve the use of polynucleotides. Under the Vical license, CytRx received an up-front payment of $3,750,000 and has the potential to receive milestone and royalty payments in the future based on criteria described in the agreement. Restrictions in the Vical license prevent us from disclosing certain of its terms, including some of the specific terms of the potential milestone and royalty payments. All amounts paid to us are non-refundable upon termination and require no additional effort on our part.
In November 2000, we entered into an exclusive, worldwide license agreement with Merck & Co., Inc. whereby we granted to Merck the right to use our TranzFect technology in DNA-based vaccines targeted to four infectious diseases, one of which is HIV. For the license to the TranzFect technology to treat the first disease target, Merck has paid us a signature payment of $2 million. In addition, in February 2002, Merck paid us a $1 million milestone fee related to the commencement by Merck of the first U.S. Food and Drug Administration Phase I Study for the first product incorporating TranzFect designed for the prevention and treatment of HIV. Merck may pay us additional milestone and product approval payments in the future of up to $3 million as they develop the product. Additionally, if certain conditions are met regarding patent protection and Merck's competitive position, Merck may pay a royalty to us of 1% on net sales of products incorporating TranzFect for the first disease target. For each of the licenses to the TranzFect technology to treat the three additional disease targets, Merck will make a series of milestone and product approval payments to us totaling up to $2,850,000 each. If and when sales of products incorporating TranzFect for the three additional disease targets commence, we will receive royalties of between 2 and 4% of the net sales from such products. Additionally, if certain conditions are met regarding patent protection and Merck's competitive position, Merck may pay an additional royalty of 1% on net sales of products incorporating TranzFect for these additional disease targets. Merck will also pay an annual fee of between $50,000 and $100,000 until the first product approval for one of the three additional disease targets. Merck may terminate the license at any time, upon 90 days written notice. All amounts paid to us are non-refundable upon termination and require no additional effort on our part.
In April 2000, we entered into a private equity line of credit agreement whereby we have the right to put shares of our common stock to an investor from time to time to raise up to $5,000,000, subject to the conditions and restrictions included in the agreement. Our ability to raise significant funds through this mechanism is subject to a number of risks and uncertainties, including stock market conditions and our ability to obtain and maintain an effective registration of the related shares with the Securities and Exchange Commission. To date, we have not exercised our right to sell shares under this agreement.
We are seeking government support for additional clinical studies of CRL-5861 (FLOCOR) in sickle cell disease. Based on the encouraging results we observed in children in the previous Phase III clinical study of CARL, we have collaborated with a consortium of pediatric hematology centers led by Johns Hopkins University School of Medicine to design a follow-up Phase III trial to further investigate CARL in children with sickle cell crisis. Johns Hopkins University School of Medicine, in cooperation with the Maryland Medical Research Institute, has submitted grant applications to the National Heart, Lung and Blood Institute of the National Institutes of Health (NHLBI) for financial support of the trial. We expect the NHLBI to make funding decisions with regard to these grant applications during the third quarter of 2002. We also continue to engage in discussions with third parties for the possible license of CRL-5861.
On February 11, 2002, we entered into a merger agreement with Global Genomics Capital, Inc. ("GGC") whereby CytRx will acquire GGC, a privately held genomics holding company, through a merger of a wholly owned subsidiary of CytRx into GGC. The closing of the transaction is anticipated in the second quarter of 2002, and is contingent upon approval by the shareholders of each company and other customary closing conditions. If our proposed merger with GGC is completed, we will become obligated under contracts with our Chief Executive Officer and other officers to make cash payments to such officers of up to $1.2 million in the aggregate upon termination of their employment for severance, stay bonuses and other benefits.
We cannot assure our stockholders that the merger with GGC, if it closes, will have a positive impact on CytRx, our financial condition or results of operations, or the trading price of our Common Stock.
We believe that we will have adequate working capital to allow us to operate through early 2003, but that additional funds will be needed to significantly advance any of our technologies under development. Some of our
additional capital requirements may be provided by the equity line of credit agreement and by potential milestone payments pursuant to the Merck and Vical licenses, but we will also pursue other sources of equity capital. The results of our technology licensing efforts and/or the actual proceeds of any fund-raising activities will determine our ongoing ability to operate as a going concern with the current portfolio of technologies under development. These efforts are subject to market conditions and our ability to identify parties that are willing and able to enter into such arrangements on terms that are satisfactory to us. There is no assurance that such funding will be available to finance our operations on acceptable terms, if at all. Insufficient funding may require us to delay, reduce or eliminate some or all of our research and development activities, planned clinical trials and administrative programs.
At December 31, 2001, we had consolidated net operating loss carryforwards for income tax purposes of approximately $54.1 million, which will expire in 2003 through 2020 if not utilized. We also have research and development tax credits and orphan drug tax credits available to reduce income taxes, if any, of approximately $6.7 million, which will expire in 2003 through 2021 if not utilized. Based on an assessment of all available evidence including, but not limited to, our limited operating history and lack of profitability, uncertainties of the commercial viability of our technology, the impact of government regulation and healthcare reform initiatives, and other risks normally associated with biotechnology companies, we have concluded that it is more likely than not that these net operating loss carryforwards and credits will not be realized and, as a result, a 100% deferred tax valuation allowance has been recorded against these assets.
The above statements regarding our plans and expectations for future financing are forward-looking statements that are subject to a number of risks and uncertainties. Our ability to obtain future financings through joint ventures, product licensing arrangements, equity financings or otherwise is subject to market conditions and our ability to identify parties that are willing and able to enter into such arrangements on terms that are satisfactory to us. There can be no assurance that we will be able to obtain future financing from these sources. Additionally, depending upon the outcome of our fund raising efforts, the accompanying financial information may not necessarily be indicative of future operating results or future financial condition.
Results of Operations
We recorded a net loss of $931,000 for the year ended December 31, 2001 as compared to net losses of $348,000 for 2000 and $15,029,000 for 1999. Loss from continuing operations was $931,000, $1,147,000 and $15,270,000 in 2001, 2000 and 1999, respectively.
Since 1996 we have marketed the services of a small group of human resource professionals to third parties under the name of Spectrum Recruitment Research as a way of offsetting our cost of maintaining this function. Service revenues related to Spectrum were $101,000 in 2001, $451,000 in 2000 and $323,000 in 1999. Cost of service revenues was $71,000 in 2001, $268,000 in 2000 and $240,000 in 1999, or 70%, 59% and 74% of service revenues, respectively. As more thoroughly discussed in Note 16 to CytRx's consolidated financial statements below, the operations of Spectrum were terminated in February 2002.
Interest income was $162,000 in 2001 as compared to $170,000 in 2000 and $463,000 in 1999. The variance between years is attributable primarily to fluctuating cash balances. License fee income of $3,751,000 in 2001 and $2,000,000 in 2000 relates to our licenses of TranzFect to Vical and Merck, respectively (see Note 12 to financial statements). Grant income was $157,000 in 2001 versus $349,000 in 2000 and $464,000 in 1999; the higher amount during 1999 is primarily due to a $445,000 grant from the U.S. Food and Drug Administration's Division of Orphan Drug Development to support our Phase III clinical trial of FLOCOR during 1998 and 1999. Other income was $228,000, $358,000 and $142,000 in 2001, 2000 and 1999, respectively. Other income for 2000 includes $225,000 in fees paid to us by Merck pursuant to an evaluation agreement for our TranzFect technology and pursuant to a fee for service agreement whereby we provided certain chemistry services to Merck.
Research and development expenses during 2001 were $1,844,000 versus $1,962,000 in 2000 and $12,812,000 in 1999. Research and development expenses were higher in 1999 primarily due to our clinical development activities for CRL-5861 (FLOCOR). In March 1998, we began a Phase III trial of CRL-5861 for treatment of acute sickle cell crisis, which was completed in December 1999. During 1999, we also continued our Phase I trial of CRL-5861 for treatment of Acute Chest Syndrome in sickle cell patients and initiated two additional clinical
trials of CRL-5861--a Phase III study investigated repeat use of FLOCOR in patients with acute sickle cell crisis and a Phase I/II study for treatment of Acute Lung Injury. Subsequent to the completion of the Phase III trial, we reduced our clinical development activities for CRL-5861 pending further analysis of the Phase III results. Our development activities during 2000 and 2001 have consisted primarily of analysis of the Phase III results, consultation with our scientific and regulatory advisors and meetings with regulatory authorities regarding preparation for the next clinical activities for CRL-5861. The Phase III study did not achieve the high level of statistical significance required by the FDA for the study as a whole; the results in children, however, were statistically significant and our planned future studies will focus on the pediatric sickle cell population. Based on our recent conversations with the FDA, it is likely that either two small additional pivotal trials or one large trial will be required for approval, along with one to two additional safety studies. During 2001 we also initiated additional preclinical studies investigating the use of CRL-5861 in the areas of cancer and spinal cord injury.
Selling, general and administrative expenses during 2001 were $3,416,000 as compared to $2,245,000 in 2000 and $3,610,000 in 1999. We recorded non-cash charges of $1,441,000, $365,000 and $1,043,000 during 2001, 2000 and 1999, respectively, related to the issuance of stock warrants to certain consultants and certain vesting events for management stock options. Excluding these charges, selling, general and administrative expenses were $1,975,000, $1,880,000 and $2,567,000 during 2001, 2000 and 1999, respectively. The decrease from 1999 to 2000 reflects staff reductions and other measures we took during the first quarter of 2000 to reduce our expenses and conserve cash resources.
Discontinued Operations
Net income (loss) from the discontinued operations of Titermax and Vaxcel (net of minority interest) was $-0-, $799,000 and $241,000 in 2001, 2000 and 1999. See Note 13 to financial statements. The following table presents the breakdown of net income (loss) from discontinued operations.
2001 2000 1999 ---- -------- -------- Titermax: Operations.......................... -- 119,000 281,000 Gain on sale of business............ -- 680,000 -- --- -------- -------- -- 799,000 281,000 Vaxcel: Operations.......................... -- -- (44,000) Minority interest................... -- -- 4,000 --- -------- -------- -- -- (40,000) --- -------- -------- Net income from discontinued operations $-- $799,000 $241,000 === ======== ======== |
Risk Factors
Any investment in CytRx involves a high degree of risk. You should carefully consider each of the following risks and all of the other information set forth in this Form 10-K. If any of the following risks actually occur, our business prospects, financial condition and results of operations could be materially adversely affected and the trading price of our common stock could decline. In any such case, you could lose all or part of your investment in our company.
We May Not Be Able to Obtain Adequate Funds to Continue Product Testing and Research and Development, Which Will Severely Reduce or Terminate Our Operations and Could Negatively Impact Our Future Profitability and Growth.
On December 31, 2001, we had approximately $5.3 million in cash and cash equivalents and working capital of $4.4 million. Our products are governed by extensive U.S. regulation and foreign regulation in other countries where we test and intend to market our current and future products. Approval of a product can take several years
and requires substantial capital resources. We do not currently have adequate funds to conduct the required testing and data collection necessary for the Food and Drug Administration, or FDA, to approve FLOCOR or any of our other products. As a result, we must either severely reduce or terminate testing and research and development activities, or obtain additional financing from third parties to fund the required testing. If we elect to attempt to obtain additional financing, we may be unable to obtain funds from any third party on terms that we believe are acceptable. Our inability to obtain additional financing would require us to severely reduce or terminate testing and research and development activities and could result in the termination of our operations. We do not currently have enough funds to complete the required testing and data collections necessary to obtain regulatory approval of FLOCOR or any of our other products currently under development or to manufacture, market, and distribute any products that may obtain FDA approval. Delays in regulatory approval will cause substantial unanticipated costs. We need to raise additional funds through equity or debt financing, or a combination of both. We may be unable to obtain any financing or financing on acceptable terms. Any financing may be on terms that dilute our stockholders. A lack of financing would require us to severely reduce or terminate testing and research and development activities and could result in the termination of our operations.
We Have No Significant Source of Revenue From Our Operations and If We Are Unable to Generate Revenues From Our Operations We May Have to Depend on Third Parties to Raise Funds.
We currently have no significant source of operating revenue. Our total revenues for 2001 were approximately $4.4 million, which included $3.75 million in license fees and $547,000 from other non-operating sources. If the FDA does not approve, for commercial sale, FLOCOR or one of our other products, we may not be able to generate significant revenues for an extended period of time. Lack of revenues adequate to satisfy our operating needs will cause us to depend on equity or debt financing, or a combination of both.
We Have Operated at a Loss For Over Five Years and Will Likely Continue to Operate at a Loss For Some Time.
We incurred significant net losses for each of the last five years. Since our inception, we have primarily conducted research and development of our products. The costs of our research and development and our lack of operating revenues has resulted in our net losses. We will probably incur losses until one or more of our products is approved by the FDA and that product has achieved significant sales volume. The activities required for the FDA review process of a new pharmaceutical are extremely costly and usually take several years. We may never obtain FDA approval of any of our products currently under development.
The Nasdaq National Market May Delist Our Common Stock and If We Are Delisted There May Not Be an Active Trading Market for Our Common Stock.
Our ability to remain listed on the Nasdaq National Market will depend on our ability to satisfy applicable Nasdaq criteria, including our ability to maintain a minimum bid price of $1.00 per share. Our minimum bid price has been below the Nasdaq required $1.00 since August 14, 2001. In addition, until November 1, 2002, in order to remain listed on the Nasdaq National Market, we must maintain at least $4 million in "net tangible assets" (defined as total assets minus total liabilities minus goodwill minus redeemable securities). After November 1, 2002, we must satisfy a minimum stockholders' equity requirement of $10 million to remain listed on the Nasdaq National Market, rather than the "net tangible assets" criteria. As of December 31, 2001, our net tangible assets were $6.6 million and as of December 31, 2001, our stockholders' equity was $6.6 million.
If we fail to continue to satisfy any of the above criteria, Nasdaq may begin procedures to remove our common stock from the Nasdaq National Market. If we are delisted from the Nasdaq National Market, an active trading market for our common stock may no longer exist.
We May Be Unable to Successfully Develop or Commercialize Our Products, Which Would Severely Reduce or Terminate Our Operations.
Our continued operations substantially depend on our ability to successfully develop and commercialize our products. In a Phase III clinical study, a drug is tested in a large patient population to provide a thorough understanding of the drug's effectiveness, benefits and the range of possible side effects. A Phase III study must be successfully completed before a company can request FDA approval for marketing the drug. In December 1999, we reported results from our Phase III clinical study of FLOCOR for treatment of sickle cell disease patients experiencing an acute vaso-occlusive crisis (a blockage of blood flow caused by deformed, or "sickled" red blood cells). Overall, the study did not achieve the statistical target for its primary objective, which was to decrease the length of vaso-occlusive crisis for the study population as a whole. To collect adequate information for FDA approval, we will need to conduct additional clinical studies, which we will not begin unless we are able to raise additional funds. Even if we are able to obtain FDA approval of one or more of our products, we may not have adequate financial or other resources, or expertise to commercialize, market and distribute those products successfully. If we do not have adequate resources or the expertise to commercialize our products successfully, we may rely on third parties to provide financial or other resources to help us commercialize those products or we may have such third parties market and distribute our products for us. In order to enter into any such arrangements with a third party, we may have to give up some or all of our rights to some of our products. We may be unable to find a third party willing to provide us with resources or to market and distribute our products. Even if we find a willing third party, we may not be able to reach an agreement on terms that we believe are acceptable.
We Depend on a Limited Number of Suppliers For an Adequate Supply of Materials, Which May Negatively Affect Our Ability to Manufacture Our Products.
We require three suppliers of materials or services to manufacture FLOCOR. These consist of a supplier of poloxamer 188, which is the raw material used to manufacture FLOCOR (the raw drug substance), a manufacturer who can refine the raw drug substance to our specifications (the purified drug substance), and a manufacturer who can mix the purified drug substance with other inactive ingredients in a sterile environment to produce the final dosage form of FLOCOR. Our inability to maintain relationships with those suppliers could result in lengthy delays in the FDA and other regulatory agencies approval processes, causing us to incur substantial unanticipated costs or our inability to produce, market and distribute our product. We have not entered into an agreement with any supplier for the raw drug substance because we believe that it is widely available. In August 1999, we entered into a long-term commercial supply contract with Organichem Corp. of Rensselaer, New York to obtain the purified drug substance. We have also entered into an agreement with the Hospital Products Division of Abbott Laboratories for the manufacture of our finished drug product. If we are unable to maintain those relationships on terms acceptable to us or to replace such suppliers if they fail to adequately perform, we will experience delays in clinical trials or commercialization of our products.
We May Incur Substantial Costs and Liability From Product Liability Claims.
If any of our products are alleged defective, they may expose us to claims for personal injury. Even if the commercialization of one or more of our products is approved by the FDA, users may claim that such product caused unintended adverse effects. We currently carry product liability insurance covering the use of our products in human clinical trials and may extend that coverage to third parties who collaborate with us on the development of our products. However, if someone asserts a claim against us and the amount of such claim exceeds our policy limits or is not covered by our policy, such successful claim may exceed our financial resources and cause us to discontinue operations. Even if claims asserted against us are unsuccessful, they may divert management's attention from our operations and we may have to incur substantial costs to defend such claims.
We May Experience Volatility in Our Stock Price, Which May Negatively Impact Your Investment.
The market price of our common stock has experienced significant volatility in the past and may continue to experience significant volatility from time to time. Our stock price has ranged from $0.45 to $6.44 over the past five years. Factors such as the following may affect such volatility:
. our quarterly operating results;
. announcements of regulatory developments or technological innovations by us or our competitors;
. government regulation of drug pricing;
. developments in patent or other technology ownership rights; and
. public concern regarding the safety of our products.
Other factors which may affect our stock price are general changes in the economy, financial markets or the pharmaceutical or biotechnology industries.
Our Anti-Takeover Provisions May Limit Stockholder Value.
We have a shareholder rights plan and provisions in our bylaws that may discourage or prevent a person or group from acquiring us without our board of directors' approval. The intent of the shareholder rights plan and our bylaw provisions is to protect our shareholders' interests by encouraging anyone seeking control of CytRx to negotiate with our board of directors.
We have a classified board of directors, which requires that at least two annual stockholder meetings, instead of one, will be required to effect a change in the majority control of our board of directors without our board of director's prior consent. This provision applies to every election of directors, not just an election occurring after a change in control. The classification of our board increases the amount of time it takes to change majority control of our board of directors and may cause our potential purchasers to lose interest in the potential purchase of us, regardless of whether our purchase would be beneficial to us and our stockholders. Our bylaws provide that directors may only be removed for cause by the affirmative vote of the holders of at least a majority of the outstanding shares of our capital stock then entitled to vote at an election of directors. This provision prevents stockholders from removing any incumbent director without cause.
Our bylaws also provide that a stockholder must give us at least 120 days notice of a proposal or director nomination that such stockholder desires to present at any annual meeting or special meeting of stockholders. Such provision prevents a stockholder from making a proposal or director nomination at a stockholder meeting without us having advance notice of that proposal or director nomination. This could make a change in control more difficult by providing our directors with more time to prepare an opposition to a proposed change in control.
Item 7A. Qualitative and Quantitative Disclosures About Market Risk
Our financial instruments that are sensitive to changes in interest rates are our investments. As of December 31, 2001, we held no investments other than amounts invested in money market accounts. We are not subject to any other material market risks.
Item 8. Financial Statements and Supplementary Data
Our consolidated financial statements and supplemental schedule and the notes thereto as of December 31, 2001 and 2000, and for each of the three years ended December 31, 2001, 2000 and 1999, together with the independent auditors' report thereon, are set forth on pages F-1 to F-18 of this Annual Report on Form 10-K.
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
None.
PART III
Item 10. Directors and Executive Officers of the Registrant
Information with respect to this item is incorporated herein by reference from the section entitled "CytRx Management" of the Proxy Statement.
Item 11. Executive Compensation
Information with respect to this item is incorporated herein by reference from the section entitled "CytRx Management" of the Proxy Statement.
Item 12. Security Ownership of Certain Beneficial Owners and Management
Information with respect to this item is incorporated herein by reference from the section entitled "CytRx Management" of the Proxy Statement.
Item 13. Certain Relationships and Related Transactions
Information with respect to this item is incorporated herein by reference from the section entitled "CytRx Management" of the Proxy Statement.
PART IV
Item 14. Exhibits, Financial Statement Schedules, and Reports on Form 8-K
(a) Documents filed as part of this 10-K:
(1) Financial Statements
The consolidated financial statements of the Company and the related report of independent auditors thereon are set forth on pages F-1 to F-17 of this Annual Report on Form 10-K. These consolidated financial statements are as follows:
Consolidated Balance Sheets as of December 31, 2001 and 2000
Consolidated Statements of Operations for the Years Ended December 31, 2001, 2000 and 1999
Consolidated Statements of Stockholders' Equity for the Years Ended December 31, 2001, 2000 and 1999
Consolidated Statements of Cash Flows for the Years Ended December 31, 2001, 2000 and 1999
Notes to Consolidated Financial Statements
Report of Independent Auditors
(2) Financial Statement Schedules
The following financial statement schedule is set forth on page F-18 of this Annual Report on Form 10-K.
Schedule II--Valuation and Qualifying Accounts for the years ended December 31, 2001, 2000 and 1999
All other schedules are omitted because they are not required, not applicable, or the information is provided in the financial statements or notes thereto.
(3) Exhibits
See Exhibit Index on page 19 of this Annual Report on Form 10-K.
(b) Reports on Form 8-K
On December 21, 2001 the Registrant filed a Current Report on Form 8-K reporting the license of its TranzFect technology to Vical, Incorporated.
CytRx Corporation
Form 10-K Exhibit Index
Exhibit Number ------ 2.1 Agreement and Plan of Merger dated February 11, 2002 among CytRx Corporation, GGC Merger Corporation and Global Genomics Capital, Inc. 3.1 Restated Certificate of Incorporation (a) 3.2 Restated By-Laws (b) 4.1 Shareholder Protection Rights Agreement dated April 16, 1997 between CytRx Corporation and American Stock Transfer & Trust Company as Rights Agent (c) 4.2 Amendment No. 1 to Shareholder Protection Rights Agreement 10.1 Agreement with Emory University, as amended (d) 10.2 Agreement with BASF Corporation, as amended (d) 10.3 * Amended and Restated Employment Agreement between CytRx Corporation and Jack J. Luchese (i) 10.4 * Amendment No. 1 to Employment Agreement with Jack J. Luchese 10.5 * Amended and Restated Change of Control Employment Agreement between CytRx Corporation and Jack J. Luchese (i) 10.6 * Amendment No. 1 to Change in Control Employment Agreement with Jack J. Luchese 10.7 * 1986 Stock Option Plan, as amended and restated (f) 10.8 * 1994 Stock Option Plan, as amended and restated (e) 10.9 * 1995 Stock Option Plan (g) 10.10 * 1998 Long-Term Incentive Plan (h) 10.11 * 2000 Long-Term Incentive Plan (l) 10.12 * Amendment No. 1 to 2000 Long-Term Incentive Plan 10.13 * Amendment No. 2 to 2000 Long-Term Incentive Plan 10.14 Purchase and Sale Agreement dated February 23, 1998 by and between CytRx Corporation and Alexandria Real Estate Equities, Inc. (h) 10.15 Common Stock Purchase Agreement dated March 24, 2000 by and between CytRx Corporation and the Investors Signatory Thereto (i) 10.16 Private Equity Line of Credit Agreement dated April 26, 2000, between CytRx Corporation and Majorlink Holdings Limited (j) 10.17 + License Agreement dated November 1, 2000 by and between CytRx Corporation and Merck & Co., Inc. (k) 10.18 License Agreement dated February 16, 2001 by and between CytRx Corporation and Ivy Animal Health, Inc. (l) 10.19 ++ License Agreement dated December 7, 2001 by and between CytRx Corporation and Vical Incorporated (m) 21.1 Subsidiaries 23.1 Consent of Ernst & Young LLP |
(d) Incorporated by reference to the Registrant's Registration Statement on
Form S-l (File No. 33-8390) filed on November 5, 1986.
(e) Incorporated by reference to the Registrant's Quarterly Report on Form 10-Q
filed on November 13, 1997.
(f) Incorporated by reference to the Registrant's Annual Report on Form 10-K
filed on March 27, 1996.
(g) Incorporated by reference to the Registrant's Registration Statement on
Form S-8 (File No. 33-93818) filed on June 22, 1995.
(h) Incorporated by reference to the Registrant's Annual Report on Form 10-K
filed on March 30, 1998.
(i) Incorporated by reference to the Registrant's Annual Report on Form 10-K
filed on March 30, 2000.
(j) Incorporated by reference to the Registrant's Registration Statement on
Form S-1 filed on June 21, 2000.
(k) Incorporated by reference to the Registrant's Current Report on Form 8-K/A
filed on March 16, 2001.
(l) Incorporated by reference to the Registrant's Annual Report on Form 10-K
filed on March 27, 2001.
(m) Incorporated by reference to the Registrant's Current Report on Form 8-K
filed on December 21, 2001.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
CYTRX CORPORATION
/s/ JACK J. LUCHESE By: ----------------------------------- Jack J. Luchese, President and Chief Executive Officer (Principal Executive Officer) Date: March 29, 2002 |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
Signature Title Date --------- ----- ---- /s/ ALEXANDER L. CAPPELLO Director March 29, 2002 ----------------------------- Alexander L. Cappello /s/ RAYMOND C. CARNAHAN, JR. Director March 29, 2002 ----------------------------- Raymond C. Carnahan, Jr. /s/ MAX LINK Chairman of the Board of March 29, 2002 ----------------------------- Directors Max Link /s/ JACK J. LUCHESE Director President and Chief March 29, 2002 ----------------------------- Executive Officer Jack J. Luchese (Principal Executive Officer) /s/ HERBERT H. MCDADE, JR. Director March 29, 2002 ----------------------------- Herbert H. McDade, Jr. /s/ MARK W. REYNOLDS Vice President, Finance March 29, 2002 ----------------------------- (Principal Financial Mark W. Reynolds Officer) |
CYTRX CORPORATION
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
AND FINANCIAL STATEMENT SCHEDULE
Consolidated Balance Sheets....................... F-2 Consolidated Statements of Operations............. F-3 Consolidated Statements of Stockholders' Equity... F-4 Consolidated Statements of Cash Flows............. F-5 Notes to Consolidated Financial Statements........ F-6 Report of Independent Auditors.................... F-17 Financial Statement Schedule Schedule II--Valuation and Qualifying Accounts. F-18 |
CYTRX CORPORATION
CONSOLIDATED BALANCE SHEETS
December 31, -------------------------- 2001 2000 ------------ ------------ ASSETS Current assets: Cash and cash equivalents................................................... $ 5,272,914 $ 3,779,376 Accounts receivable, less allowances of $39,050 in 2001 and $11,900 in 2000...................................................................... 28,000 54,160 Current portion of note receivable.......................................... 122,467 110,859 Other current assets........................................................ 23,238 34,171 ------------ ------------ Total current assets.................................................... 5,446,619 3,978,566 Property and equipment, net.................................................... 1,745,728 2,331,977 Other assets: Note receivable............................................................. 365,249 487,717 Other assets................................................................ 53,000 60,978 ------------ ------------ Total other assets...................................................... 418,249 548,695 ------------ ------------ Total assets............................................................ $ 7,610,596 $ 6,859,238 ============ ============ LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable............................................................ $ 178,777 $ 298,236 Accrued expenses and other current liabilities.............................. 849,068 942,188 ------------ ------------ Total current liabilities............................................... 1,027,845 1,240,424 Commitments Stockholders' equity: Preferred Stock, $.01 par value, 1,000 shares authorized, including 1,000 shares of Series A Junior Participating Preferred Stock; no shares issued and outstanding........................................................... -- -- Common stock, $.001 par value, 50,000,000 shares authorized; 11,459,012 and 10,734,012 shares issued at December 31, 2001 and 2000, respectively.............................................................. 11,459 10,734 Additional paid-in capital.................................................. 74,632,292 72,737,739 Treasury stock, at cost (633,816 shares held at December 31, 2001 and 2000)..................................................................... (2,279,238) (2,279,238) Accumulated deficit......................................................... (65,781,762) (64,850,421) ------------ ------------ Total stockholders' equity.............................................. 6,582,751 5,618,814 ------------ ------------ Total liabilities and stockholders' equity.............................. $ 7,610,596 $ 6,859,238 ============ ============ |
See accompanying notes.
CYTRX CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
Year Ended December 31, -------------------------------------- 2001 2000 1999 ----------- ----------- ------------ Revenues: Service revenues.................................. $ 101,463 $ 451,031 $ 322,536 License fees...................................... 3,751,000 2,000,000 -- Interest income................................... 162,284 170,433 462,634 Grant revenue..................................... 156,729 348,790 464,442 Other............................................. 227,934 357,604 141,848 ----------- ----------- ------------ 4,399,410 3,327,858 1,391,460 Expenses: Cost of service revenues.......................... 70,501 267,915 239,840 Research and development.......................... 1,844,038 1,962,171 12,811,925 Selling, general and administrative............... 3,416,212 2,245,229 3,609,613 ----------- ----------- ------------ 5,330,751 4,475,315 16,661,378 ----------- ----------- ------------ Loss from continuing operations...................... (931,341) (1,147,457) (15,269,918) Income (loss) from discontinued operations........... -- 799,355 236,730 Minority interest in discontinued operations......... -- -- (3,897) ----------- ----------- ------------ Net loss............................................. $ (931,341) $ (348,102) $(15,029,291) =========== =========== ============ Basic and diluted income (loss) per common share: Continuing operations............................. $ (0.09) $ (0.12) $ (1.99) Discontinued operations........................... -- 0.08 0.03 ----------- ----------- ------------ Net loss.......................................... $ (0.09) $ (0.04) $ (1.96) =========== =========== ============ Basic and diluted weighted average shares outstanding 10,358,381 9,423,787 7,652,227 |
See accompanying notes.
CYTRX CORPORATION
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
Common Stock ------------------ Additional Shares Paid-in Accumulated Treasury Issued Amount Capital Deficit Stock Total ---------- ------- ----------- ------------ ----------- ------------ Balance at December 31, 1998............. 8,236,926 $ 8,237 $66,423,577 $(49,473,028) $(2,270,238) $ 14,688,548 Issuance of common stock............. 136,927 137 339,078 -- -- 339,215 Issuance of stock options/warrants... -- -- 1,043,216 -- -- 1,043,216 Purchase of treasury stock........... -- -- -- -- (9,000) (9,000) Net loss............................. -- -- -- (15,029,291) -- (15,029,291) ---------- ------- ----------- ------------ ----------- ------------ Balance at December 31, 1999............. 8,373,853 8,374 67,805,871 (64,502,319) (2,279,238) 1,032,688 Issuance of common stock............. 2,360,159 2,360 4,567,255 -- -- 4,569,615 Issuance of stock options/warrants... -- -- 364,613 364,613 Net loss............................. -- -- -- (348,102) -- (348,102) ---------- ------- ----------- ------------ ----------- ------------ Balance at December 31, 2000............. 10,734,012 10,734 72,737,739 (64,850,421) (2,279,238) 5,618,814 Issuance of common stock............. 725,000 725 453,619 -- -- 454,344 Issuance of stock options/warrants... -- -- 1,440,934 -- -- 1,440,934 Net loss............................. -- -- -- (931,341) -- (931,341) ---------- ------- ----------- ------------ ----------- ------------ Balance at December 31, 2001............. 11,459,012 $11,459 $74,632,292 $(65,781,762) $(2,279,238) $ 6,582,751 ========== ======= =========== ============ =========== ============ |
See accompanying notes.
CYTRX CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
Year Ended December 31, ------------------------------------- 2001 2000 1999 ---------- ----------- ------------ Cash flows from operating activities: Net loss........................................................ $ (931,341) $ (348,102) $(15,029,291) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation................................................ 586,249 317,850 68,377 Gain on sales of segment operations......................... -- (679,784) (240,196) Minority interest in net loss of subsidiary................. -- -- (3,897) Stock option and warrant expense............................ 1,440,934 364,613 1,043,216 Changes in assets and liabilities: Receivables.............................................. 26,160 52,811 (91,043) Inventories.............................................. -- 3,585 4,455 Notes receivable......................................... 110,860 51,424 300,000 Other assets............................................. 18,911 198,454 (93,675) Accounts payable......................................... (119,459) 124,868 546,019 Other liabilities........................................ (93,120) (1,435,841) 1,950,233 ---------- ----------- ------------ Total adjustments............................................... 1,970,535 (1,002,020) 3,483,489 ---------- ----------- ------------ Net cash provided by (used in) operating activities......... 1,039,194 (1,350,122) (11,545,802) Cash flows from investing activities: Maturities of held-to-maturity securities....................... -- -- 6,417,066 Net proceeds from sales of segment operations................... -- 100,000 240,196 Net proceeds from sale of technology............................ -- -- 600,000 Capital (expenditures) retirements, net......................... -- (28,032) (2,515,157) ---------- ----------- ------------ Net cash provided by investing activities................... -- 71,968 4,742,105 Cash flows from financing activities: Net proceeds from issuance of common stock...................... 454,344 2,225,637 339,215 Redemption/retirement of debt................................... -- (200,000) -- Purchase of treasury stock...................................... -- -- (9,000) Proceeds from issuance of debt, net of issuance costs........... -- -- 650,000 ---------- ----------- ------------ Net cash provided by financing activities................... 454,344 2,025,637 980,215 ---------- ----------- ------------ Net increase (decrease) in cash and cash equivalents............... 1,493,538 747,483 (5,823,482) Cash and cash equivalents at beginning of year..................... 3,779,376 3,031,893 8,855,375 ---------- ----------- ------------ Cash and cash equivalents at end of year........................... $5,272,914 $ 3,779,376 $ 3,031,893 ========== =========== ============ |
See accompanying notes
CYTRX CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. Nature of Business
CytRx Corporation ("CytRx" or "the Company") is a biopharmaceutical company focused on the development and commercialization of high-value human therapeutics. The Company's current research and development include CRL-5861, an intravenous agent for treatment of sickle cell disease and other acute vaso-occlusive disorders, and TranzFect, a delivery technology for DNA-based vaccines. CytRx also has a research pipeline with opportunities in the areas of muscular dystrophy, cancer, spinal cord injury, vaccine delivery and gene therapy.
The Company's sales relate to Spectrum Recruitment Research ("Spectrum"), through which the Company markets the services of its small group of human resources professionals as a way of offsetting the Company's cost of maintaining this function. Spectrum's services are marketed primarily within metropolitan Atlanta, Georgia. The Company's operational focus is on the development and commercialization of pharmaceutical products; the Spectrum operations were formed as an ancillary activity. As more thoroughly discussed in Note 16, the operations of Spectrum were terminated in February 2002.
2. Summary of Significant Accounting Policies
Basis of Presentation--The consolidated financial statements include the accounts of CytRx together with those of its majority-owned subsidiaries. Certain prior year amounts have been reclassified to conform to the 2001 financial statement presentation. As more thoroughly discussed in Note 13, the operations of Vaxcel, Inc. and the Company's TiterMax business segment are presented as discontinued operations for all periods presented.
Revenue Recognition--Service revenues are recognized at the time services are rendered. The Company does not require collateral or other securities for sales made on credit. Revenues from collaborative research arrangements and grants are generally recorded as the related costs are incurred. The costs incurred under such arrangements are recorded as research and development expense and approximated the revenues reported in the accompanying statements of operations. Non-refundable license fee revenue is recognized upon receipt when no continuing involvement of the Company is required and payment of the license fee represents the culmination of the earnings process. Non-refundable license fees received subject to future performance by the Company or that are credited against future payments due to the Company are deferred until services are performed, future payments are received or termination of the agreement, whichever is earlier.
Cash Equivalents--The Company considers all highly liquid debt instruments with an original maturity of 90 days or less to be cash equivalents. Cash equivalents consist primarily of commercial paper and amounts invested in money market accounts.
Fair Value of Financial Instruments--The carrying amounts reported in the balance sheet for cash and cash equivalents, accounts receivable, notes receivable and accounts payable approximate their fair values.
Property and Equipment--Property and equipment are stated at cost and depreciated using the straight-line method based on the estimated useful lives (generally five years for equipment and furniture) of the related assets. Leasehold improvements are amortized over the term of the related lease or other contractual arrangement. Management continuously monitors and evaluates the realizability of recorded long-lived assets to determine whether their carrying values have been impaired. In accordance with Financial Accounting Standards Board ("FASB") Statement No. 121, Accounting for the Impairment of Long-Lived Assets, the Company records impairment losses on long-lived assets used in operations when events and circumstances indicate that the assets might be impaired and the nondiscounted cash flows estimated to be generated by those assets are less than the
CYTRX CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
carrying amount of those assets. Any impairment loss is measured by comparing the fair value of the asset to its carrying amount.
Patents and Patent Application Costs--Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived therefrom is uncertain. Patent costs are therefore expensed rather than capitalized.
Accrued Expenses--Accrued expenses and other current liabilities at December 31 are summarized below (in thousands).
2001 2000 ---- ---- Clinical research activities $194 $378 Deferred revenue............ 303 256 Other miscellaneous......... 352 308 ---- ---- Total................ $849 $942 ==== ==== |
Basic and Diluted Loss per Common Share--Basic and diluted loss per share are computed based on the weighted average number of common shares outstanding. Common share equivalents (which may consist of options and warrants) are excluded from the computation of diluted loss per share since the effect would be antidilutive.
Shares Reserved for Future Issuance--As of December 31, 2001, the Company has reserved approximately 3,566,000 of its authorized but unissued shares of common stock for future issuance pursuant to its employee stock option plans and warrants, and 5,612,000 shares pursuant to warrants issued to consultants and investors.
Stock-based Compensation--The Company grants stock options and warrants for a fixed number of shares to key employees and directors with an exercise price equal to the fair market value of the shares at the date of grant. The Company accounts for stock option grants and warrants in accordance with APB Opinion No. 25, Accounting for Stock Issued to Employees ("APB 25") and related Interpretations, and, accordingly, recognizes no compensation expense for the stock option grants and warrants for which the terms are fixed. For stock option grants and warrants which vest based on certain corporate performance criteria, compensation expense is recognized to the extent that the quoted market price per share exceeds the exercise price on the date such criteria are achieved or are probable. In October 1995, the FASB issued Statement of Financial Accounting Standards No. 123, Accounting for Stock-based Compensation ("Statement 123"), which provides an alternative to APB 25 in accounting for stock-based compensation issued to employees. However, the Company has continued to account for stock-based compensation in accordance with APB 25 (See Note 8). The Company has also granted stock options and warrants to certain consultants and other third parties. Stock options and warrants granted to consultants and other third parties are accounted for in accordance with Emerging Issues Task Force ("EITF") No. 96-18, Accounting for Equity Instruments That Are Issued for Sales of Goods and Services to Other Than Employees, and are valued at the fair market value of the options and warrants granted or the services received, whichever is more reliably measurable. Expense is recognized in the period in which a performance commitment exists or the period in which the services are received, whichever is earlier.
Concentrations of Credit Risk--Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and cash equivalents, accounts receivable and note receivable. The Company maintains cash and cash equivalents in large well-capitalized financial institutions and the Company's investment policy disallows investment in any debt securities rated less than "investment-grade"
CYTRX CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
by national ratings services. The Company generally does not require collateral from its customers. The Company is at risk to the extent accounts receivable and note receivable amounts become uncollectible.
Use of Estimates--The preparation of the financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.
Recently Issued Accounting Standards-- In December 1999, the SEC staff issued Staff Accounting Bulletin No. 101, Revenue Recognition in Financial Statements ("SAB 101"). SAB 101 explains how the SEC staff applies by analogy the existing rules on revenue recognition to other transactions not covered by such rules. In March 2000, the SEC issued SAB 101A that delayed the original effective date of SAB 101 until the second quarter of 2000 for calendar year companies. In June 2000, the SEC issued SAB 101B that further delayed the effective date of SAB 101 until no later than the fourth fiscal quarter of fiscal years beginning after December 15, 1999. The adoption of SAB 101 has not had a material impact on the Company's financial statements.
In June 2001, the FASB issued SFAS No. 141, Business Combinations ("SFAS 141"). This statement eliminates the pooling of interests method of accounting for all business combinations initiated after June 30, 2001, and addresses the initial recognition and measurement of goodwill and other intangible assets acquired in a business combination. On February 11, 2002, the Company entered into an agreement to acquire Global Genomics Capital, Inc., a privately held genomics company in Los Angeles, California, through a merger of a wholly owned subsidiary of the Company into Global Genomics Capital. The merger is subject to the shareholder approval of both companies and other customary closing conditions. See Note 16. The Company intends to account for the merger in accordance with the provisions of SFAS 141.
In June 2001, the FASB issued SFAS No. 142, Goodwill and Other Intangible Assets ("SFAS 142"). This statement changes the accounting for goodwill from an amortization method to an impairment only approach. SFAS 142 is not expected to have a significant impact on the results of operations of the Company upon adoption.
In August 2001, the FASB issued SFAS No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets ("SFAS 144"), which addresses financial accounting and reporting for the impairment or disposal of long-lived assets and supercedes SFAS No. 121, Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed Of, and the accounting and reporting provisions of APB Opinion No. 30, Reporting the Results of Operations, for a disposal of a segment of a business. SFAS 144 is effective for fiscal years beginning after December 15, 2001, with earlier application encouraged. The Company expects to adopt SFAS 144 as of January 1, 2002. In February 2002, the Company transferred all of its ownership rights in Spectrum Recruitment Research to Albert, Isaac & Alexander, Inc., a consulting firm comprised of former CytRx (Spectrum) employees. Since the disposal of Spectrum occurred after the balance sheet date, the Company has not restated its financial statements to reflect Spectrum as a discontinued operation in accordance with the transition provisions of SFAS 144. See Note 16.
CYTRX CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
3. Property and Equipment
Property and equipment at December 31 consist of the following (in thousands):
2001 2000 ------- ------ Equipment and furnishings.... $ 2,122 $2,122 Leasehold improvements....... 984 984 ------- ------ 3,106 3,106 Less accumulated depreciation (1,360) (774) ------- ------ $ 1,746 $2,332 ======= ====== |
4. Exchange of Common Stock for Cancellation of Accounts Payable, Accrued Expenses and Debt
During the first quarter of 2000, the Company reached agreements with certain trade creditors whereby an aggregate of $1,894,000 of trade payables was cancelled in exchange for the issuance of approximately 758,000 shares of CytRx's Common Stock. The Company also cancelled $650,000 of Long-Term Debt in exchange for a cash payment of $200,000 and the issuance of 180,000 shares of CytRx's Common Stock.
5. Private Placement of Common Stock
Effective March 24, 2000, the Company entered into a Stock Purchase Agreement with certain investors (the "Investors") whereby the Investors agreed to purchase 800,000 shares of the Company's Common Stock for an aggregate purchase price of $1,800,000 and the issuance of warrants to purchase an additional 330,891 shares at $2.25 per share. After consideration of offering expenses, net proceeds to the Company were approximately $1,649,000. The warrants expire March 31, 2003. The Investors were granted registration rights for the shares issued to them and the shares underlying the warrants. Subject to certain conditions, the Investors were also required, upon effective registration of the shares, to either (a) purchase an additional 286,000 shares at $2.25 per share and simultaneously receive an additional three-year warrant to purchase 143,000 shares at $2.25 per share, or (b) purchase 429,000 shares at a price equal to 75% of a trailing average market price of the Company's Common Stock, as defined in the Stock Purchase Agreement. In July 2000, the Investors exercised their rights to purchase 429,000 additional shares at a net price of $.77 per share, resulting in net proceeds of $307,000 to the Company, after consideration of offering expenses.
6. Equity Line of Credit
In April 2000, the Company entered into a Private Equity Line of Credit Agreement (the "ELC Agreement") with Majorlink Holdings Limited ("Majorlink"), pursuant to which the Company has the right to put shares of Common Stock to Majorlink from time to time during the "commitment period" to raise up to $5,000,000, subject to certain conditions and restrictions. The "commitment period" began on the effective date (May 3, 2001) of a registration statement filed by the Company to register the resale by Majorlink of the shares of Common Stock that Majorlink purchases under the ELC Agreement and ends on the earliest of (1) the date thirty months from such date, (2) the date on which Majorlink shall have purchased $5,000,000 of Common Stock under the ELC Agreement or (3) the date either party terminates the ELC Agreement in accordance with its terms. Each time the Company desires to raise a specific amount of cash under the ELC Agreement, the Company will issue to Majorlink a number of shares of Common Stock determined by dividing the amount of cash desired to be raised by the Company by 90% of a trailing market average price of the Company's Common Stock, as defined in the ELC Agreement. No shares were purchased by Majorlink under the ELC Agreement in
CYTRX CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
2001 or 2000. In connection with the ELC Agreement, the Company issued Majorlink a warrant to purchase up to 150,000 shares of Common Stock at a per share exercise price of $2.25. The warrant is exercisable for a period of three years.
7. Commitments and Contingencies
Rental expense from continuing operations under operating leases during 2001, 2000 and 1999 approximated $154,000, $160,000 and $212,000, respectively. Minimum annual future obligations for operating leases are $172,000, $179,000, $185,000, $193,000, $200,000 and $285,000 in 2002, 2003, 2004, 2005, 2006 and 2007 and beyond, respectively. Aggregate minimum future subrentals the Company expects to receive under noncancellable subleases total approximately $106,000 at December 31, 2001.
8. Stock Options and Warrants
CytRx has stock option plans pursuant to which certain key employees, directors and consultants are eligible to receive incentive and/or nonqualified stock options to purchase shares of CytRx's common stock. Fixed options granted under the plans generally become exercisable over a three year period from the dates of grant and have lives of ten years. Certain options granted to the Company's executive officers and others contain alternative or additional vesting provisions based on the achievement of corporate objectives. Additionally, the Company has granted warrants to purchase shares of the Company's common stock to its President and Chief Executive Officer subject to vesting criteria as set forth in his warrant agreements; such warrants have lives of ten years from the dates of grant. Exercise prices of all options and warrants for employees and directors are set at the fair market values of the common stock on the dates of grant. During 2001, 2000 and 1999, the vesting criteria for certain options and warrants held by employees were achieved, resulting in $0, $115,000 and $689,000 of compensation expense, respectively.
The terms of certain employee stock options and warrants were modified during 2001 and 2000. As a result of the modifications, these certain employee options and warrants are required to be accounted for as variable options under APB 25 and related Interpretations. Depending on the ultimate vesting of these certain employee options and warrants, compensation expense of up to $56,000 may be recognized by the Company. No compensation expense related to these certain employee options and warrants was required to be recognized in 2001 and 2000.
In addition, the Company repriced certain outstanding employee options and warrants in the current year. As a result of the modification, these certain employee options and warrants are required to be accounted for as variable options under APB 25 and related Interpretations. Potential compensation expense is measured for each reporting period based on the intrinsic value of these employee options and warrants until the options or warrants are ultimately exercised, forfeited, cancelled or expire unexercised. No compensation expense was recognized for the year ended December 31, 2001 related to these employee options and warrants.
During 2001, 2000 and 1999, services were received in exchange for options and warrants issued to certain consultants, resulting in aggregate non-cash charges of $1,441,000, $249,000 and $355,000, respectively. Such charges for 2001 included $1,063,000 related to 1,272,492 warrants issued to Cappello Capital Corp. for financial advisory services. Alexander L. Cappello, a member of the Company's Board of Directors, is Chairman and CEO of Cappello Group, Inc., parent of Cappello Capital Corp.
CYTRX CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
A summary of the Company's stock option and warrant activity and related information for the years ended December 31 is shown below.
Weighted Average Options and Warrants Exercise Price ---------------------------------- ----------------- 2001 2000 1999 2001 2000 1999 ---------- ---------- ---------- ----- ----- ----- Outstanding--beginning of year............ 3,685,682 3,137,852 2,258,308 $1.57 $1.43 $1.17 Granted................................... 2,404,297 1,416,803 961,750 1.03 2.04 2.25 Exercised................................. (500,000) (106,567) (12,103) 0.50 1.28 1.00 Forfeited................................. (7,501) (741,989) (70,103) 1.45 1.86 5.91 Expired................................... (50,000) (20,417) -- 1.00 1.00 -- ---------- ---------- ---------- Outstanding--end of year.................. 5,532,478 3,685,682 3,137,852 $1.22 $1.57 $1.43 ========== ========== ========== Exercisable at end of year................ 4,764,137 2,917,674 2,170,107 $1.26 $1.47 $1.25 Weighted average fair value of options and warrants granted during the year........ $ 0.66 $ 1.98 $ 1.59 |
The following table summarizes additional information concerning options and warrants outstanding and exercisable at December 31, 2001:
Options Outstanding Options Exercisable ----------------------------------------------- -------------------- Weighted Average Weighted Weighted Remaining Average Number Of Average Range of Number of Contractual Exercise Shares Exercise Exercise Prices Shares Life (years) Price Exercisable Price --------------- --------- ------------ -------- ----------- -------- $0.81 - 1.50 4,785,675 6.6 $1.02 4,017,334 $1.03 2.00 - 3.43 741,803 1.2 2.45 741,803 2.45 7.75 5,000 3.2 7.75 5,000 7.75 --------- --------- 5,532,478 5.9 1.22 4,764,137 1.26 ========= ========= |
The Company has elected to follow APB 25 and related Interpretations in accounting for employee stock options and warrants because, as discussed below, the alternative fair value accounting provided for under Statement 123 requires use of option valuation models that were not developed for use in valuing employee stock options.
Pro forma information regarding net loss and loss per share is required by Statement 123, which also requires that the information be determined as if the Company had accounted for employee stock options granted and warrants issued subsequent to December 31, 1994 under the fair value method of that Statement. The fair value for the Company's options and warrants was estimated at the date of grant using a Black-Scholes option pricing model with the following assumptions:
2001 2000 1999 ---- ---- ----- Weighted average risk free interest rate........................ 5.29% 6.24% 6.27% Dividend yields................................................. 0% 0% 0% Volatility factors of the expected market price of the Company's common stock.................................................. 0.98 1.03 1.046 Weighted average life of the option (years)..................... 7.2 8 8 |
CYTRX CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including the expected stock price volatility. Because the Company's employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management's opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.
For purposes of pro forma disclosures, the estimated fair value of the employee options and warrants is amortized to expense over the options' vesting periods. The Company's pro forma information is as follows (in thousands, except per share data):
2001 2000 1999 ------- ------ -------- Pro forma net loss.............................. $(1,594) $ (941) $(16,505) Pro forma net loss per share (basic and diluted) $ (0.15) $(0.10) $ (2.16) |
9. Shareholder Protection Rights Plan
Effective April 16, 1997, the Company's Board of Directors declared a distribution of one Right for each outstanding share of the Company's common stock to stockholders of record at the close of business on May 15, 1997 and for each share of common stock issued by the Company thereafter and prior to a Flip-in Date (as defined below). Each Right entitles the registered holder to purchase from the Company one-ten thousandth ( 1/10000th) of a share of Series A Junior Participating Preferred Stock, at an exercise price of $30. The Rights are generally not exercisable until 10 business days after an announcement by the Company that a person or group of affiliated persons (an "Acquiring Person") has acquired beneficial ownership of 15% or more of the Company's then outstanding shares of common stock (a "Flip-in Date"). In connection with the merger agreement with Global Genomics Capital, the Company's Board of Directors amended the shareholders protection rights agreement to exempt the merger from triggering a Flip-in Date.
In the event the Rights become exercisable as a result of the acquisition of shares, each Right will enable the owner, other than the Acquiring Person, to purchase at the Right's then current exercise price a number of shares of common stock with a market value equal to twice the exercise price. In addition, unless the Acquiring Person owns more than 50% of the outstanding shares of common stock, the Board of Directors may elect to exchange all outstanding Rights (other than those owned by such Acquiring Person) at an exchange ratio of one share of common stock per Right. All Rights that are owned by any person on or after the date such person becomes an Acquiring Person will be null and void.
The Rights have been distributed to protect the Company's stockholders from coercive or abusive takeover tactics and to give the Board of Directors more negotiating leverage in dealing with prospective acquirors.
10. Retirement Plan
The Company maintained a defined contribution retirement plan (the "Plan") covering employees of the Company until February 2000, at which time the Plan was terminated. Total expense for the Plan for the years ended December 31, 2001, 2000 and 1999 was approximately $0, $0 and $69,000, respectively.
CYTRX CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
11. Income Taxes
For income tax purposes, CytRx and its subsidiaries have an aggregate of approximately $54.1 million of net operating losses available to offset against future taxable income, subject to certain limitations. Such losses expire in 2003 through 2020 as of December 31, 2001. CytRx also has an aggregate of approximately $6.7 million of research and development and orphan drug credits available for offset against future income taxes that expire in 2003 through 2021.
Deferred income taxes reflect the net effect of temporary differences between the financial reporting carrying amounts of assets and liabilities and income tax carrying amounts of assets and liabilities. The components of the Company's deferred tax assets and liabilities are as follows (in thousands):
December 31, ------------------ 2001 2000 -------- -------- Deferred tax assets: Net operating loss carryforward........ $ 20,564 $ 20,590 Tax credit carryforward................ 6,667 6,652 Other.................................. 2,584 2,822 -------- -------- Total deferred tax assets.......... 29,815 30,064 Deferred tax liabilities: Depreciation and other................. (2,727) (2,882) -------- -------- Total deferred tax liabilities..... (2,727) (2,882) -------- -------- Net deferred tax assets................... 27,088 27,182 Valuation allowance....................... (27,088) (27,182) -------- -------- $ -- $ -- ======== ======== |
Based on assessments of all available evidence as of December 31, 2001 and 2000, management has concluded that the respective deferred income tax assets should be reduced by valuation allowances equal to the amounts of the deferred income tax assets.
12. License Agreements
Ivy Animal Health, Inc.
In February 2001, CytRx entered into a license agreement with Ivy Animal Health, Inc. ("Ivy") of Overland Park, Kansas, whereby CytRx granted to Ivy a worldwide exclusive license to its investigational agent, CRL-8761, a non-antibiotic feed additive that enhances growth performance in monogastric food animals such as poultry and pigs. As part of the license, CytRx received a nominal upfront payment, and will receive a milestone fee upon regulatory approval in the United States and an eventual royalty equal to 5% of net sales.
Vical, Incorporated
On December 7, 2001, CytRx entered into a license agreement (the "Vical License") with Vical Incorporated ("Vical") granting Vical exclusive, worldwide rights to use or sublicense CytRx's TranzFect poloxamer technology to enhance viral or non-viral delivery of polynucleotides (such as DNA and RNA) in all preventive and therapeutic human and animal health applications, except for (1) four infectious disease vaccine targets previously licensed by CytRx to Merck, and (2) DNA vaccines or therapeutics based on prostate-specific
CYTRX CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
membrane antigen (PSMA). In addition, the Vical License permits Vical to use TranzFect poloxamer technology to enhance the delivery of proteins in prime-boost vaccine applications that involve the use of polynucleotides. Under the Vical License, CytRx received an up-front payment of $3,750,000 and has the potential to receive milestone and royalty payments in the future based on criteria described in the agreement. The Company has no commitment for continuing involvement to earn the upfront payment or the future milestone payments.
Merck & Co., Inc.
In November 2000, CytRx entered into an exclusive, worldwide license agreement with Merck and Company, Inc. ("Merck") whereby CytRx granted to Merck rights to use its TranzFect technology in DNA-based vaccines targeted to four infectious diseases. In addition to an upfront payment of $2 million for the first disease target, in February 2002 Merck paid CytRx a $1 million milestone fee related to the commencement by Merck of the first U.S. Food and Drug Administration Phase I Study for the first product incorporating TranzFect designed for the prevention and treatment of HIV. In addition, Merck may pay CytRx milestone and product approval payments of up to $3 million as they develop the product. The Company has no commitment for continuing involvement to earn the upfront payment or the future milestone payments. Thus, the $2 million upfront payment was recognized as license fee revenue in 2000 and the $1 million milestone payment will be recognized as license fee revenue in 2002. Additionally, if certain conditions are met regarding patent protection and Merck's competitive position, Merck may pay a royalty to CytRx of 1% on net sales of products incorporating TranzFect for the first disease target. For each of the licenses for the three additional disease targets, Merck will pay to CytRx a series of milestone and product approval payments totaling up to $2,850,000 each. If and when sales of products incorporating TranzFect for the three additional disease targets commence, CytRx will receive royalties of between 2 and 4% of the net sales from such products. Additionally, if certain conditions are met regarding patent protection and Merck's competitive position, Merck may pay an additional royalty to CytRx of 1% on net sales of products incorporating TranzFect for these additional disease targets, in which case the total royalties may be up to 5%.
13. Discontinued Operations
Titermax
From 1987 to 2000 CytRx manufactured, marketed and distributed Titermax, an adjuvant used to produce immune responses in research animals. Effective June 15, 2000, the Company entered into a Purchase Agreement with Titermax USA, Inc. (an unaffiliated company) whereby Titermax USA purchased the worldwide rights to market and distribute Titermax, including all accounts receivable, inventory and other assets used in the Titermax business. The gross purchase price was $750,000, consisting of $100,000 in cash and a $650,000 five-year secured promissory note bearing interest of 10% annually. Net income associated with the Titermax activities included in income (loss) from discontinued operations was approximately $119,000 and $281,000 for 2000 and 1999, respectively. A gain related to the sale of $680,000 was recorded in 2000 and is also classified as discontinued operations.
Vaxcel, Inc.
On June 2, 1999, CytRx entered into a Stock Acquisition Agreement with A-Z Professional Consultants, Inc. ("A-Z") for the sale of CytRx's equity interest in Vaxcel, Inc The sale was consummated on September 9, 1999. Pursuant to the agreement, A-Z purchased 9,625,000 shares of common stock of Vaxcel from CytRx for a cash purchase price of $319,000. Net loss (net of minority interest) associated with Vaxcel included in income (loss) from discontinued operations was approximately $40,000 for the year ended December 31, 1999.
CYTRX CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
14. Segment Reporting
The Company has four reportable segments: Recruiting Services (Spectrum), Product Development (core business of development and commercialization of pharmaceutical-related products), Research Products (TiterMax) and Vaccine Development (Vaxcel). See Notes 1 and 13 for additional information concerning these operations.
The Company adopted FASB Statement No. 131, Disclosures About Segments of an Enterprise and Related Information, in 1998 which outlines the way the Company reports information about its operating segments. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies (see Note 2). The Company evaluates performance of its operating segments based primarily on profit or loss from operations before income taxes. Summarized financial information concerning the Company's reportable segments is shown in the following table.
Continuing Operations Discontinued Operations -------------------------------- --------------------------------- Total Total Product Recruiting Continuing Research Vaccine Discontinued Development Services Operations Products Development Operations (in thousands) ----------- ---------- ---------- -------- ----------- ------------ 2001: Sales to external customers......... $ -- $101 $ 101 $ -- $ -- $ -- Intersegment sales.................. -- -- -- -- -- -- Collaborative, grant & other revenue 4,136 -- 4,136 -- -- -- Interest income..................... 162 -- 162 -- -- -- Interest expense.................... -- -- -- -- -- -- Depreciation and amortization....... 586 -- 586 -- -- -- Segment profit (loss)............... (913) (18) (931) -- -- -- Total assets........................ 7,611 -- 7,611 -- -- -- Capital expenditures................ -- -- -- -- -- -- Stock option and warrant expense.... 1,441 -- 1,441 -- -- -- 2000: Sales to external customers......... $ -- $451 $ 451 $170 $ -- $170 Intersegment sales.................. -- -- -- -- -- -- Collaborative, grant & other revenue 2,706 -- 2,706 -- -- -- Interest income..................... 170 -- 170 -- -- -- Interest expense.................... -- -- -- -- -- -- Depreciation and amortization....... 318 -- 318 -- -- -- Segment profit (loss)............... (1,293) 146 (1,147) 799 -- 799 Total assets........................ 6,859 -- 6,859 -- -- -- Capital expenditures................ 20 -- 20 -- -- -- Stock option and warrant expense.... 365 -- 365 -- -- -- 1999: Sales to external customers......... $ -- $323 $ 323 $500 $ -- $500 Intersegment sales.................. -- -- -- -- -- Collaborative, grant & other revenue 606 -- 606 -- 134 134 Interest income..................... 463 -- 463 -- 7 7 Interest expense.................... -- -- -- -- 4 4 Depreciation and amortization....... 62 -- 62 -- 6 6 Segment profit (loss)............... (15,345) 75 (15,270) 281 (40) 241 Total assets........................ 6,128 -- 6,128 -- -- -- Capital expenditures................ 2,515 -- 2,515 -- -- -- Stock option and warrant expense.... 1,043 -- 1,043 -- -- -- |
CYTRX CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
15. Quarterly Financial Data (unaudited)
Summarized quarterly financial data for 2001 and 2000 is as follows (in thousands, except per share data):
Quarter Ended ------------------------------------------ March 31 June 30 September 30 December 31 -------- ------- ------------ ----------- 2001 Net sales........................................ $ 26 $ 10 $ 28 $ 37 Gross profit..................................... 13 3 7 7 Income loss from continuing operations........... (1,157) (1,220) (1,002) 2,448 Income from discontinued operations.............. -- -- -- -- Net income (loss)................................ (1,157) (1,220) (1,002) 2,448 Basic and diluted income (loss) per common share: Continuing operations......................... (0.11) (0.12) (0.10) 0.23 Discontinued operations....................... -- -- -- -- Net income (loss)............................. (0.11) (0.12) (0.10) 0.23 2000 Net sales........................................ $ 100 $ 85 $ 168 $ 98 Gross profit..................................... 48 41 86 8 Income (loss) from continuing operations......... (940) (762) (606) 1,161 Income from discontinued operations.............. 40 759 -- -- Net income (loss)................................ (900) (3) (606) 1,161 Basic and diluted income (loss) per common share: Continuing operations......................... (0.12) (0.08) (0.06) 0.11 Discontinued operations....................... 0.01 0.08 -- -- Net income (loss)............................. (0.11) (0.00) (0.06) 0.11 |
16. Subsequent Events
Transfer of Spectrum Operations
Since 1996 CytRx has marketed the services of its small group of human resources professionals under the name of Spectrum Recruitment Research ("Spectrum") as a way of offsetting the Company's cost of maintaining this function. In February 2002 the operations of Spectrum were terminated and the rights to use the Spectrum tradenames were transferred to Albert, Isaac & Alexander, Inc., a consulting firm comprised of former CytRx (Spectrum) employees. Net income (loss) associated with the Spectrum activities included in income (loss) from operations was approximately $(18,000), $146,000 and $75,000 for 2001, 2000, and 1999, respectively.
The Company has accounted for the disposal of Spectrum in accordance with the provisions of SFAS 144. Accordingly, the results of operations of Spectrum are included in continuing operations for the years ended December 31, 2001, 2000 and 1999 since the criteria for assets held for sale for this disposal group as outlined in SFAS 144 were not met.
Pending Merger with Global Genomics Capital, Inc.
On February 11, 2002, the Company entered into an agreement whereby the Company will acquire Global Genomics Capital, Inc. ("GGC"), a privately held genomics holding company, through a merger of a wholly owned subsidiary of the Company into GGC. The terms of the merger provide for CytRx to acquire all outstanding shares of GGC in return for the issuance or reservation for issuance of a maximum of approximately 9,963,000 shares of CytRx Common Stock, subject to adjustment. The closing of the transaction is anticipated in the second quarter of 2002, and is contingent upon approval by the shareholders of each company and other customary closing conditions. If the merger with GGC is completed, the Company will become obligated under contracts with its officers to make cash payments of up to $1.2 million in the aggregate upon termination of their employment.
REPORT OF INDEPENDENT AUDITORS
The Board of Directors and Stockholders
Cyt Rx Corporation
We have audited the accompanying consolidated balance sheets of CytRx Corporation as of December 31, 2001 and 2000, and the related consolidated statements of operations, stockholders' equity, and cash flows for each of the three years in the period ended December 31, 2001. Our audits also included the financial statement schedule listed in the Index at Item 14(a). These financial statements and schedule are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements and schedule based on our audits.
We conducted our audits in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of CytRx Corporation at December 31, 2001 and 2000 and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2001, in conformity with accounting principles generally accepted in the United States. Also, in our opinion, the related financial statement schedule, when considered in relation to the basic financial statements taken as a whole, presents fairly in all material respects the information set forth therein.
/s/ ERNST & YOUNG LLP Atlanta, Georgia March 1, 2002 |
CYTRX CORPORATION
SCHEDULE II--VALUATION AND QUALIFYING ACCOUNTS
FOR THE YEARS ENDED DECEMBER 31, 2001, 2000 AND 1999
Additions ------------------- - Balance at Charged to Charged Beginning of Costs and to Other Balance at Description Period Expenses Accounts Deductions End of Period ----------- ------------ ---------- -------- ---------- ------------- Reserve Deducted in the Balance Sheet from the Asset to Which it Applies: Allowance for Bad Debts Year ended December 31, 2001....... $ 11,900 $ 27,150 $-- $ -- $ 39,050 Year ended December 31, 2000....... -- 11,900 -- -- 11,900 Year ended December 31, 1999....... -- -- -- -- -- Allowance for Deferred Tax Assets Year ended December 31, 2001....... $27,182,000 $ -- $-- $94,000 $27,088,000 Year ended December 31, 2000....... 26,364,000 818,000 -- -- 27,182,000 Year ended December 31, 1999....... 20,769,000 5,595,000 -- -- 26,364,000 |
Exhibit 2.1
AGREEMENT AND PLAN OF MERGER
Dated as of February 11, 2002
among
CytRx Corporation,
GGC MERGER CORPORATION
AND
Global Genomics Capital, Inc.
Exhibit 2.1
AGREEMENT AND PLAN OF MERGER
C. The Board, has, after consultation with the Independent Advisor, and in light of and subject to the terms and conditions set forth herein, (i) determined that (x) the Merger is fair to CytRx and its stockholders from a financial point of view, and (y) the Merger is advisable and in the best interests of CytRx and its stockholders, (ii) adopted and approved this Agreement, and (iii) determined to recommend that the stockholders of CytRx vote to approve the issuance of the Merger Consideration in accordance with this Agreement and the amendment to CytRx's certificate of incorporation as contemplated in this Agreement;
D. The board of directors and sole shareholder of Merger Sub have adopted and approved this Agreement, and the board of directors of GGC has adopted and approved this Agreement and has determined to recommend that the shareholders of GGC approve this Agreement;
F. GGC, CytRx and Merger Sub desire to make certain representations, warranties, covenants and agreements in connection with the merger and also to prescribe various conditions to the Merger.
Certain capitalized terms used in this Agreement are defined in Section 9.2 of this Agreement
Now, therefore, upon the above premises and in consideration of the mutual promises, covenants, representations and warranties contained herein, the parties hereto agree as follows:
ARTICLE I
THE MERGER
(a) The directors of GGC immediately prior to the Effective Time shall be the directors of the Surviving Corporation, until the earlier of their resignation or removal or until their respective successors are duly elected and qualified, as the case may be.
(b) The officers of GGC immediately prior to the Effective Time shall be the officers of the Surviving Corporation, until the earlier of their resignation or removal or until their respective successors are duly elected and qualified, as the case may be.
ARTICLE II
CANCELLATION OF THE CAPITAL STOCK OF GGC
AND EXCHANGE WITH RESPECT THERETO
(a) subject to the other provisions of Article II, each share of common stock of GGC issued and outstanding immediately prior to the Effective Time (other than Dissenting Shares) shall be converted into the right to receive a number of shares of CytRx Common Stock equal to the quotient of (i) 9,962,881 divided by (ii) the sum of the total number of shares of GGC common stock outstanding at the Effective Time (including those shares issued between the date hereof and the Effective Time upon the exercise of GGC Stock Options outstanding on the date hereof), plus the number of shares of GGC common stock issuable upon the exercise of any Converting Options (as defined in Section 2.4) and any other GGC Stock Options that are
(b) each share of GGC capital stock issued and held in GGC's treasury immediately prior to the Effective Time shall, by virtue of the Merger, cease to be outstanding and shall be cancelled and retired without payment of any consideration therefor;
(c) each share of common stock, par value $.01 per share, of Merger Sub issued and outstanding immediately prior to the Effective Time shall be converted into and become one fully paid and nonassessable share of common stock of the Surviving Corporation; and
time subsequent to the Effective Time shall be delivered to the holder of any Certificate until such holder surrenders such Certificate for exchange as provided in this Article II.
(b) At the Effective Time, the Converting Options shall be converted into and become an option to purchase CytRx Common Stock, and CytRx shall assume each Converting Option, in accordance with its terms, except that from and after the Effective Time, (i) each
Converting Option assumed by CytRx hereunder may be exercised solely for shares of CytRx Common Stock, (ii) the number of shares of CytRx Common Stock subject to such Converting Option shall be equal to the number of shares of GGC common stock subject to such Converting Option immediately prior to the Effective Time multiplied by the Exchange Ratio, and (iii) the per share exercise price under each such Converting Option shall be adjusted by dividing the per share exercise price under each such Converting Option by the Exchange Ratio and rounding up to the nearest cent. CytRx shall not be obligated to issue any fraction of a share of CytRx Common Stock upon exercise of Converting Options and any fraction of a share of CytRx Common Stock that otherwise be subject to a Converting Option shall rounded to the nearest whole share.
ARTICLE III
REPRESENTATIONS AND WARRANTIES
made available to CytRx for its review and the minutes contained therein are true and complete in all material respects as in effect as of the date of this Agreement and accurately reflect all amendments thereto and all proceedings of the board of directors (including any and all committees of the board of directors) and the shareholders of GGC
(iii) All outstanding shares of GGC's capital stock are validly issued, fully paid and nonassessable and were issued free of preemptive rights (contractual or otherwise) and in compliance with applicable securities Laws. All shares of GGC common stock subject to issuance upon the exercise of GGC Stock Options will be duly authorized, validly issued, fully paid and nonassessable and free of preemptive rights and will be issued in compliance with applicable securities laws and regulations.
(iv) Except as set forth in Section 3.1(b)(i), there are no shares of capital stock or other equity securities of GGC outstanding and no Equity Rights relating to the capital stock of GGC. Except as specifically contemplated by this Agreement, no Person has any Contract or any right or privilege (whether pre-emptive or contractual) capable of becoming a Contract or Equity Right for the purchase, subscription or issuance of any securities of GGC.
Equity Right for the purchase, subscription or issuance of any securities of Blizzard. As of the date hereof, GGC holds, of record and beneficially, 1,300,444 shares of Blizzard common stock.
(i) GGC has all requisite corporate power and authority to enter into, deliver and perform this Agreement and to consummate the transactions contemplated hereby, including the Merger. The execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby, including the Merger, have been duly and validly authorized by all necessary corporate action on the part of GGC, subject to approval of the GGC shareholders. This Agreement has been duly executed and delivered by GGC and constitutes a valid and binding obligation of GGC enforceable in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other similar laws relating to or affecting creditors' rights generally and general equitable principles (whether considered in a proceeding in equity or at law).
(iii) No notice to, Consent of or filing with, any Regulatory Authority is required by or with respect to GGC in connection with the execution and delivery of this Agreement and the Certificate of Merger by GGC, the consummation by GGC of the transactions contemplated hereby and thereby, and compliance of GGC with any of the provisions hereof or thereof, except the filing of the Certificate of Merger as contemplated by Section 1.3.
(i) GGC and, to the Knowledge of GGC, each other GGC Entity have timely filed with the appropriate Taxing authorities all Tax Returns in all jurisdictions in which Tax Returns are required to be filed, and such Tax Returns are correct and complete in all respects. All Taxes of GGC and, to the Knowledge of GGC, of each other GGC Entity, whether or not shown on any Tax Return, have been fully and timely paid. There are no Liens for any Taxes (other than a Lien for current real property or ad valorem Taxes not yet due and payable) on any of the Assets of GGC and, to the Knowledge of GGC, there are no Liens for any Taxes (other than a Lien for current real property or ad valorem Taxes not yet due and payable) on any of the Assets of any other GGC Entity. No claim has ever been made by an authority in a jurisdiction where GGC does not file a Tax Return that GGC may be subject to Taxes by that jurisdiction and, to the Knowledge of GGC, no claim has ever been made by an authority in a jurisdiction where any other GGC Entity does not file a Tax Return that such GGC Entity may be subject to Taxes by that jurisdiction.
(ii) GGC has not received any notice of assessment or proposed assessment in connection with any Taxes, and there are no threatened or pending disputes, claims, audits or examinations regarding any Taxes of GGC or the Assets of GGC. None of the other GGC Entities has received any notice of assessment or proposed assessment in connection with any Taxes, and there are no threatened or pending disputes, claims, audits or examinations regarding any Taxes of any other GGC Entity or the Assets of any other GGC Entity. No officer or employee responsible for Tax matters of GGC or, to the Knowledge of GGC, of any other GGC Entity expects any Regulatory Authority to assess any additional Taxes for any period for which Tax Returns have been filed. Neither GGC nor, to the Knowledge of GGC, any other GGC Entity has waived any statute of limitations in respect of any Taxes or agreed to a Tax assessment or deficiency.
(iii) GGC, and, to the Knowledge of GGC, each other GGC Entity, has complied with all applicable Laws, rules and regulations relating to the withholding of Taxes and the payment thereof to appropriate authorities, including Taxes required to have been withheld and paid in connection with amounts paid or owing to any employee or independent contractor, and Taxes required to be withheld and paid pursuant to Sections 1441 and 1442 of the Internal Revenue Code or similar provisions under foreign Law.
(iv) The unpaid Taxes of GGC, and, to the Knowledge of GGC, each other GGC Entity (i) did not, as of the most recent fiscal month end, exceed the reserve for Tax Liability (rather than any reserve for deferred Taxes established to reflect timing differences between book and Tax income) set forth on the face of the most recent balance sheet (rather than in any notes thereto) for such GGC Entity and (ii) do not exceed that reserve as adjusted for the passage of time through the Closing Date in accordance with past custom and practice of the GGC Entities in filing their Tax Returns.
(v) Neither GGC nor, to the Knowledge of GGC, any other GGC Entity, is a party to any Tax allocation or sharing agreement and neither GGC nor, to the Knowledge of GGC, any other GGC Entity has been a member of an affiliated group filing a consolidated federal income Tax Return (other than a group the common parent of which was GGC) or has any Tax Liability of any Person under Treasury Regulation Section 1.1502-6 or any similar provision of state, local or foreign Law (other than the other members of the consolidated group of which GGC is parent), or as a transferee or successor, by contract or otherwise.
(vi) During the five-year period ending on the date hereof, neither GGC nor, to the Knowledge of GGC, any other GGC Entity was a distributing corporation or a controlled corporation in a transaction intended to be governed by Section 355 of the Internal Revenue Code.
(vii) Neither GGC nor, to the Knowledge of GGC, any other GGC
Entity has made any payments, is obligated to make any payments, or is a party
to any contract that could obligate it to make any payments that could be
disallowed as a deduction under Section 280G or 162(m) of the Internal Revenue
Code. Neither GGC nor, to the Knowledge of GGC, any other GGC Entity has been a
United States real property holding corporation within the meaning of Code
Section 897(c)(1)(A)(ii). None of the GGC Entities has been or will be required
to include any adjustment in taxable income for any Tax period (or portion
thereof) pursuant to Section 481 of the Internal Revenue Code or any comparable
provision under state or foreign Tax Laws as a result of transactions or events
occurring prior to the Closing.
(viii) GGC and, to the Knowledge of GGC, each of the other GGC Entities is in compliance with, and its records contain all information and documents (including properly completed IRS Forms W-9) necessary to comply with, all applicable information reporting and Tax withholding requirements under federal, state, and local Tax Laws, and such records identify with specificity all accounts subject to backup withholding under Code Section 3406.
(ix) Neither GGC nor, to the Knowledge of GGC, any GGC Entity, has or has had in any foreign country a permanent establishment, as defined in any applicable tax treaty or convention between the United States and such foreign country.
(ii) All Assets which are material to GGC's business held under leases or subleases by GGC, are held under valid Contracts enforceable in accordance with their respective terms (except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, or other Laws affecting the enforcement of creditors' rights generally and except that the availability of the equitable remedy of specific performance or injunctive relief is subject to the discretion of the court before which any proceedings may be brought), and each such Contract is in full force and effect. To the Knowledge of GGC, all Assets which are material to each other GGC Entity's business held under leases or subleases by such GGC Entity, are held under valid Contracts enforceable in accordance with their respective terms (except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, or other Laws affecting the enforcement of creditors' rights generally and except that the availability of the equitable remedy of specific performance or injunctive relief is subject to the discretion of the court before which any proceedings may be brought), and each such Contract is in full force and effect.
(iii) GGC and, to the Knowledge of GGC, each other GGC Entity, have maintained and currently maintain insurance in amounts, scope, and coverage that are deemed adequate by such GGC Entity's board of directors or executive management. Neither GGC nor, to the Knowledge of GGC, any other GGC Entity, has received notice from any insurance carrier that (i) any policy of insurance will be canceled or that coverage thereunder will be reduced or eliminated, or (ii) premium costs with respect to such policies of insurance will be substantially increased. To the Knowledge of GGC, there are presently no claims for amounts exceeding in any individual case $10,000 pending under such policies of insurance and no notices of claims in excess of such amounts have been given by any GGC Entity under such policies.
(iv) The Assets of GGC include all Assets required to operate the business of GGC as presently conducted.
(i) Each GGC Entity and its Operating Properties are, and have been, in compliance with all Environmental Laws.
(ii) During the period of (i) each GGC Entity's ownership or operation of any of its current properties or (ii) each GGC Entity's holding of a security interest in any Operating Property, to the Knowledge of GGC, there have been no releases, discharges, spillages, or disposals of Hazardous Material in, on, under, adjacent to, or affecting (or potentially affecting) such properties. Prior to the period of (i) any GGC Entity's ownership or operation of any of their respective current properties or (ii) any GGC Entity's holding of a security interest in any Operating Property, to the Knowledge of GGC, there were no releases, discharges, spillages, or disposals of Hazardous Material in, on, under, or affecting any such property or Operating Property.
i) Neither GGC nor, to the Knowledge of GGC, any other GGC Entity, is the subject of any Litigation asserting that it or any other GGC Entity has committed an unfair labor practice (within the meaning of the National Labor Relations Act or comparable state Law) or other violation of state or federal labor Law or seeking to compel it or any other GGC Entity to bargain with any labor organization or other employee representative as to wages or conditions of employment, nor is GGC nor, to the Knowledge of GGC, any other GGC Entity, party to any collective bargaining agreement or subject to any bargaining order, injunction or other Order relating to GGC's or any other GGC Entity's relationship or dealings with its employees, any labor organization or any other employee representative. There is no strike, slowdown, lockout or other job action or labor dispute involving GGC nor, to the Knowledge of GGC, any other GGC Entity, pending or threatened and there has been no such actions or disputes in the past five years. To the Knowledge of GGC, in the past five years, there has not been any attempt by any GGC Entity employees or any labor organization or other employee representative to organize or certify a collective bargaining unit or to engage in any other union organization activity with respect to the workforce of any GGC Entity. The employment of each employee and the engagement of each independent contractor of GGC is terminable at will by GGC without any penalty, liability or severance obligation incurred by GGC. GGC will not owe any amounts to any of its employees or independent contractors as of the Closing Date, including any amounts incurred for any wages, bonuses, vacation pay, sick leave, contract notice periods, change of control payments or severance obligations.
ii) All of GGC's employees employed in the United States are either United States citizens or are legally entitled to work in the United States under the Immigration Reform and Control Act of 1986, as amended, other United States immigration Laws and the Laws related to the employment of non-United States citizens applicable in the state in which the employees are employed.
person or entity any rights with respect to any Blizzard Intellectual Property and no other Person has any rights in or to any of the Blizzard Intellectual Property. The rights of Blizzard in and to any of the Blizzard Intellectual Property will not be limited or otherwise affected by reason of any of the transactions contemplated hereby. To GGC's Knowledge, the Blizzard Intellectual Property does not infringe and is not alleged to have infringed any trademark, copyright, patent or other proprietary right of any person. To GGC's Knowledge, each item of Blizzard Intellectual Property is valid and enforceable and there are no infringements of Blizzard's rights in and to the Blizzard Intellectual Property by any person or entity. To GGC's Knowledge, Blizzard has not entered into any consent, indemnification, forbearance to sue or settlement agreement with any person or entity relating to any item of Blizzard Intellectual Property or those of any person or entity.
(i) To GGC's Knowledge, no statement, certificate, instrument, or other writing furnished or to be furnished by any GGC Entity or any Affiliate thereof to CytRx pursuant to this Agreement or any other document, agreement, or instrument referred to herein contains or will contain any untrue statement of material fact or will omit to state a material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.
(ii) None of the information supplied or to be supplied by any GGC Entity or any Affiliate thereof for inclusion in (i) the Proxy Statement to be mailed to CytRx stockholders in connection with the CytRx Stockholders' Meeting, (ii) any materials to be delivered to GGC Shareholders in connection with the GGC Shareholders Meeting, or (iii) any other documents to be filed by a GGC Entity or any Affiliate thereof with the SEC or any other Regulatory Authority in connection with the transactions contemplated hereby, will, at the respective time such documents are filed or delivered, and with respect to the Proxy Statement, when first mailed to the stockholders of CytRx, be false or misleading with respect to any material fact, or omit to state any material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, or, in the case of the Proxy Statement or any amendment thereof or supplement thereto, at the time of the CytRx Stockholders' Meeting, be false or misleading with respect to any material fact, or omit to state any material fact necessary to correct any statement in any earlier communication with respect to the solicitation of any proxy for the CytRx Stockholders' Meeting.
(iii) All documents that any GGC Entity or any Affiliate thereof is responsible for filing with any Regulatory Authority in connection with the transactions contemplated hereby will comply as to form in all material respects with the provisions of applicable Law.
(i) CytRx and Merger Sub have all requisite corporate power and authority to enter into, deliver and perform this Agreement and to consummate the transactions contemplated hereby, subject to the approval of the issuance of the Merger Consideration by the CytRx stockholders. The execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby have been duly authorized by all necessary corporate action on the part of CytRx or Merger Sub, as the case may be, subject to the approval of the issuance of the Merger Consideration by the CytRx stockholders. Subject to such stockholder approval, this Agreement has been duly executed and delivered by CytRx and Merger Sub and constitutes a valid and binding obligation of CytRx or Merger Sub, as the case may be, enforceable in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other similar laws relating to or affecting creditors' rights generally and general equitable principles (whether considered in a proceeding in equity or at law).
(iii) No notice to, Consent of or filing with, any Regulatory Authority is required by or with respect to CytRx or Merger Sub in connection with the execution and delivery of this Agreement by CytRx and Merger Sub, the consummation by CytRx or Merger Sub, as the case may be, of the transactions contemplated hereby, and compliance by CytRx and Merger Sub with any of the provisions hereof, except (A) in connection or compliance with the provisions of the Securities Laws, applicable state corporate and securities Laws and the rules of the Nasdaq National Market, and notices to or filings with the Internal Revenue Service or the Pension Benefit Guaranty Corporation with respect to any employee benefit plans, and (B) the filing of the Certificate of Merger as contemplated by Section 1.3.
same character, type and magnitude as incurred in the past, CytRx has not incurred any liabilities or obligations of any nature, whether or not accrued, contingent or otherwise, that would have a Material Adverse Effect on CytRx. All agreements, contracts and other documents required to be filed as exhibits to any of CytRx SEC Documents have been so filed.
(i) Except as disclosed in Schedule 3.2(i)(i) to the CytRx Disclosure Letter, all CytRx Entities have timely filed with the appropriate Taxing authorities all Tax Returns in all jurisdictions in which Tax Returns are required to be filed, and such Tax Returns are correct and complete in all respects. All Taxes of the CytRx Entities (whether or not shown on any Tax Return) have been fully and timely paid. There are no Liens for any Taxes (other than a Lien for current real property or ad valorem Taxes not yet due and payable) on any of the Assets of any of the CytRx Entities. No claim has ever been made by an authority in a jurisdiction where any CytRx Entity does not file a Tax Return that such CytRx Entity may be subject to Taxes by that jurisdiction.
(ii) None of the CytRx Entities has received any notice of assessment or proposed assessment in connection with any Taxes, and there are no threatened or pending disputes, claims, audits or examinations regarding any Taxes of any CytRx Entity or the assets of any CytRx Entity. No officer or employee responsible for Tax matters of any CytRx Entity expects any Regulatory Authority to assess any additional Taxes for any period for which Tax Returns have been filed. None of the CytRx Entities has waived any statute of limitations in respect of any Taxes or agreed to a Tax assessment or deficiency.
(iii) Each CytRx Entity has complied with all applicable Laws, rules and regulations relating to the withholding of Taxes and the payment thereof to appropriate authorities, including Taxes required to have been withheld and paid in connection with amounts paid or owing to any employee or independent contractor, and Taxes required to be withheld and paid pursuant to Sections 1441 and 1442 of the Internal Revenue Code or similar provisions under foreign Law.
(iv) The unpaid Taxes of each CytRx Entity (i) did not, as of the most recent fiscal month end, exceed the reserve for Tax Liability (rather than any reserve for deferred Taxes established to reflect timing differences between book and Tax income) set forth on the face of the most recent balance sheet (rather than in any notes thereto) for such CytRx Entity and (ii) do not exceed that reserve as adjusted for the passage of time through the Closing Date in accordance with past custom and practice of the CytRx Entities in filing their Tax Returns.
(v) None of the CytRx Entities is a party to any Tax allocation or sharing agreement and none of the CytRx Entities has been a member of an affiliated group filing a consolidated federal income Tax Return (other than a group the common parent of which was CytRx) or has any Tax Liability of any Person under Treasury Regulation Section 1.1502-6 or any similar provision of state, local or foreign Law (other than the other members of the consolidated group of which CytRx is parent), or as a transferee or successor, by contract or otherwise.
(vi) During the five-year period ending on the date hereof, none of the CytRx Entities was a distributing corporation or a controlled corporation in a transaction intended to be governed by Section 355 of the Internal Revenue Code.
(vii) None of the CytRx Entities has made any payments, is
obligated to make any payments, or is a party to any contract that could
obligate it to make any payments that could be disallowed as a deduction under
Section 280G or 162(m) of the Internal Revenue Code. CytRx has not been a United
States real property holding corporation within the meaning of Internal Revenue
Code Section 897(c)(1)(A)(ii). None of the CytRx Entities has been or will be
required to include any adjustment in taxable income for any Tax period (or
portion thereof) pursuant to Section 481 of the Internal Revenue Code or any
comparable provision under state or foreign Tax Laws as a result of transactions
or events occurring prior to the Closing.
(viii) Each of the CytRx Entities is in compliance with, and its records contain all information and documents (including properly completed IRS Forms W-9) necessary to comply with, all applicable information reporting and Tax withholding requirements under federal, state, and local Tax Laws, and such records identify with specificity all accounts subject to backup withholding under Section 3406 of the Internal Revenue Code.
(ix) No CytRx Entity has or has had in any foreign country a permanent establishment, as defined in any applicable tax treaty or convention between the United States and such foreign country.
(i) Each CytRx Entity and its Operating Properties are, and have been, in compliance with all Environmental Laws.
(ii) During the period of (i) any CytRx Entity's ownership or
operation of any of their respective current properties or (ii) any CytRx
Entity's holding of a security interest in any Operating Property, to the
Knowledge of CytRx, there have been no releases, discharges, spillages, or
disposals of Hazardous Material in, on, under, adjacent to, or affecting (or
potentially affecting) such properties. Prior to the period of (i) any CytRx
Entity's ownership or operation of any of their respective current properties or
(ii) any CytRx Entity's holding of a security interest in any Operating
Property, to the Knowledge of CytRx, there were no releases, discharges,
spillages, or disposals of Hazardous Material in, on, under, or affecting any
such property or Operating Property.
(ii) Each CytRx Benefit Plan is in compliance with the terms of such CytRx Benefit Plan, in compliance with the applicable requirements of the Code, in material compliance with the applicable requirements of ERISA, and in compliance with any other applicable Laws. CytRx has not received any communication (written or unwritten) from any government agency questioning or challenging the compliance of any CytRx Benefit Plan with applicable Laws. No CytRx Benefit Plan is currently being audited by a governmental agency for compliance with applicable Laws or has been audited with a determination by the governmental agency that the Employee Benefit Plan failed to comply with applicable Laws.
(iii) There has been no oral or written representation or communication with respect to any aspect of the Employee Benefit Plans made to employees of the CytRx which is not in accordance with the written or otherwise preexisting terms and provisions of such plans. There are no unresolved claims or disputes under the terms of, or in connection with, the CytRx Benefit Plans other than claims for benefits which are payable in the ordinary course of business and no action, proceeding, prosecution, inquiry, hearing or investigation has been commenced with respect to any CytRx Benefit Plan.
(iv) All CytRx Benefit Plan documents and annual reports or returns, audited or unaudited financial statements, actuarial valuations, summary annual reports, and summary plan descriptions issued with respect to the CytRx Benefit Plans are correct and complete, have been timely filed with the IRS, the DOL or distributed to participants of the CytRx Benefit Plans (as required by Law), and there have been no changes in the information set forth therein.
(v) No "party in interest" (as defined in ERISA Section 3(14))
or "disqualified person" (as defined in Internal Revenue Code Section
4975(e)(2)) of any CytRx Benefit Plan has engaged in any nonexempt "prohibited
transaction" (described in Internal Revenue Code Section 4975(c) or ERISA
Section 406).
(vi) No Liability under Title IV of ERISA has been or is expected to be incurred by CytRx or its ERISA Affiliates and no event has occurred that could reasonably result in Liability under Title IV of ERISA being incurred by CytRx or its ERISA Affiliates with respect to any ongoing, frozen, or terminated single-employer plan of CytRx or the single-employer plan of any ERISA Affiliate. There has been no "reportable event," within the meaning of ERISA Section 4043 for which the 30-day reporting requirement has not been waived by any ongoing, frozen, or terminated single employer plan of CytRx or of an ERISA Affiliate.
(ix) The actuarial present values of all accrued deferred compensation entitlements (including entitlements under any executive compensation, supplemental retirement, or employment agreement) of employees and former employees of any CytRx Entity and their respective beneficiaries, other than entitlements accrued pursuant to funded retirement plans subject to the provisions of Code Section 412 or ERISA Section 302, have been fully reflected on the CytRx Financial Statements to the extent required by and in accordance with GAAP.
(x) All individuals who render services to any CytRx Entity and who are authorized to participate in a CytRx Benefit Plan pursuant to the terms of such CytRx Benefit Plan are in fact eligible to and authorized to participate in such CytRx Benefit Plan. All individuals participating in (or eligible to participate in) any CytRx Benefit Plan are common-law employees of a CytRx Entity.
(xi) On or after September 26, 1980, neither CytRx nor any of
its ERISA Affiliates has had an "obligation to contribute" (as defined in ERISA
Section 4212) to a "multiemployer plan" (as defined in ERISA Sections 4001(a)(3)
and 3(37)(A)).
waived any material provision of any such Contract; and (D) no other party to any such Contract is, to the Knowledge of CytRx, in Default in any respect or has repudiated or waived any material provision thereunder.
(i) To CytRx's Knowledge, no statement, certificate, instrument, or other writing furnished or to be furnished by any CytRx Entity or any Affiliate thereof to CytRx pursuant to this Agreement or any other document, agreement, or instrument referred to herein contains or will contain any untrue statement of material fact or will omit to state a material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.
(ii) None of the information supplied or to be supplied by any CytRx Entity or any Affiliate thereof for inclusion in (i) the Proxy Statement to be mailed to CytRx stockholders in connection with the CytRx Stockholders' Meeting, (ii) any materials to be delivered to GGC Shareholders in connection with the GGC Shareholder Meeting, and (iii) any other documents to be filed by a CytRx Entity or any Affiliate thereof with the SEC or any other Regulatory Authority in connection with the transactions contemplated hereby, will, at the respective time such documents are filed or delivered, and with respect to the Proxy Statement, when first mailed to the stockholders of CytRx, be false or misleading with respect to any material fact, or omit to state any material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, or, in the case of the Proxy Statement or any amendment thereof or supplement thereto, at the time of the CytRx Stockholders' Meeting, be false or misleading with respect to any material fact, or omit to state any material fact necessary to correct any statement in any earlier communication with respect to the solicitation of any proxy for the CytRx Stockholders' Meeting.
(iii) All documents that any CytRx Entity or any Affiliate thereof is responsible for filing with any Regulatory Authority in connection with the transactions contemplated hereby will comply as to form in all material respects with the provisions of applicable Law.
ARTICLE IV
COVENANTS RELATING TO CONDUCT OF BUSINESS
in the ordinary course of business and consistent with past practice and of substantially the same character, type and magnitude as dispositions in the past.
arrangement to do any of the foregoing, or (iii) enter into or renew any contract, agreement, commitment or arrangement providing for the payment to any director, officer or employee of GGC of compensation or benefits contingent, or the terms of which are materially altered, upon the occurrence of any of the transactions contemplated by this Agreement.
options that are outstanding as of the date hereof, (ii) in satisfaction of severance obligations to employees and officers or (iii) to pay the fees and expenses of Cappello Capital Corp.
ARTICLE V
ADDITIONAL AGREEMENTS
comments from the SEC or its staff and of any request by the SEC or its staff for amendments or supplements to the Proxy Statement or for additional information and will supply GGC with copies of all correspondence between CytRx or any of its representatives, on the one hand, and the SEC or its staff, on the other hand, with respect to the Proxy Statement or the Merger. If at any time prior to the CytRx Stockholders' Meeting there shall occur any event that should be set forth in an amendment or supplement to the Proxy Statement, CytRx will promptly prepare and mail to its stockholders such an amendment or supplement. CytRx will not mail any Proxy Statement, or any amendment or supplement thereto, to which GGC reasonably objects. GGC shall cooperate with CytRx in the preparation of the Proxy Statement and will provide any information or documents reasonably requested by CytRx for inclusion in the Proxy Statement. CytRx shall include in the Proxy Statement reasonable disclosure regarding the anticipated cash balance of CytRx at Closing (assuming that the Closing occurs on May 31, 2002) and the assumptions made by CytRx in determining such anticipated cash balance.
(c) GGC shall as promptly as practicable prepare materials to be provided to the GGC Shareholders in connection with the GGC Shareholders Meeting and cause such materials to be mailed to the GGC Shareholders at the earliest practical time. Such materials shall include, without limitation: (i) copies of certain CytRx SEC Documents as requested by CytRx, (ii) copies of this Agreement and the other agreements contemplated hereby and (iii) investor questionnaires and other documents that CytRx reasonably requests the GGC Shareholders to execute and deliver in connection with the Merger. If at any time prior to the GGC Shareholders Meeting there shall occur any event that requires additional or revised materials to be sent to the GGC Shareholders, GGC and CytRx will promptly prepare and mail to the GGC Shareholders such additional or revised materials. GGC will not mail any materials to the GGC Shareholders to which CytRx reasonably objects. GGC will take all actions reasonably requested by CytRx, including delivering documents to and gathering responses from the GGC Shareholders in connection with satisfying CytRx of the availability of applicable securities Laws exemptions from registration for the issuance of the Merger Consideration hereunder.
from its stockholders entitled to vote at the CytRx Stockholders' Meeting proxies in favor of issuance of the Merger Consideration and shall take all other action necessary or, in the judgment of CytRx, helpful to secure the vote or consent of such holders required by the DGCL or this Agreement to effect the Merger.
(b) GGC shall call the GGC Shareholders Meeting to be held as promptly as practicable for the purpose of voting upon the Merger. GGC will, through its board of directors, recommend to its shareholders approval of the Merger. GGC shall take all action necessary or, in the judgment of GGC, helpful to (i) secure the vote or consent of the GGC Shareholders required by the CCC or this Agreement to effect the Merger and (ii) cause its shareholders to execute and deliver to CytRx any documents reasonably requested by CytRx to be executed by the GGC Shareholders in connection with the Merger.
(a) As of the Effective Time, the articles of incorporation of the Surviving Corporation shall contain provisions no less favorable with respect to indemnification than are set forth in the articles of incorporation of GGC, which provisions shall not be amended, repealed or otherwise modified for a period of six years from the Effective Time in any manner that would adversely affect the rights thereunder of individuals who at the Effective Time were directors or officers of GGC. From and after the Effective Time, for a period of six years, CytRx shall (i) cause the Surviving Corporation to indemnify the directors and officers of GGC and (ii) indemnify the members of the CytRx board of directors and the officers of CytRx immediately prior to the Effective Time (the "Existing CytRx Directors and Officers"), on terms no less favorable than the provisions with respect to indemnification that are set forth in the certificate of incorporation of CytRx as of the Effective Time.
(b) The provisions of CytRx's certificate of incorporation and bylaws with respect to indemnification of CytRx directors and officers shall not be amended, repealed or otherwise modified for a period of six years from the Effective Time in any manner that would adversely affect the rights thereunder of individuals who at the Effective Time were directors or officers of GGC or who were Existing CytRx Directors and Officers.
(c) From and after the date hereof and for three (3) years from the Effective Time, CytRx shall maintain continuously in effect directors' and officers' liability insurance covering the Existing CytRx Directors and Officers for actions taken or omissions occurring at or prior to the Effective Time on terms which in the aggregate are not less favorable than the more favorable of (1) the terms of CytRx's current insurance coverage or (2) the directors' and officers' liability insurance provided by CytRx after the Effective Time to directors or officers of CytRx who are not Existing CytRx Directors and Officers. In addition, CytRx shall take all actions necessary to add Jack J. Luchese and Mark W. Reynolds as additional notice parties with respect to termination, renewal and other notices regarding all of such policies of directors' and officers' liability insurance. If at any time prior to the expiration of such three year period CytRx elects to change its insurance carrier with respect to its directors' and officers' liability insurance, CytRx shall purchase tail coverage. Notwithstanding any of the above, prior to the Effective Time, CytRx may purchase a prepaid extended reporting (or tail) binder on its existing directors' and officers' liability insurance policy.
(d) CytRx and GGC agree that the Existing CytRx Directors and Officers and the directors and officers of GGC immediately prior to the Effective Time covered hereby are intended to be third party beneficiaries under this Section 5.5 and shall have the right to enforce the obligations of the Surviving Corporation and CytRx.
initially two of which shall be Steven A. Kriegsman and Louis Ignarro, Ph.D., and a third member shall be determined by GGC prior to the date of the filing of the Proxy Statement, subject to the reasonable approval of the CytRx board of directors, and (iii) a seventh director who shall be determined by a majority of the three CytRx-designated directors and a majority of the three GGC-designated directors. CytRx and GGC hereby agree that, for a period of two years after the Effective Time, at least three (3) members of the Board must be Eligible CytRx Directors.
(a) an extension of the existing investment banking agreement with Cappello Capital Corp.;
(a) Prior to the Effective Time, each party shall permit the other to make or cause to be made such investigation of the business and properties of it and its Subsidiaries and of their respective financial and legal conditions as may be reasonably requested, provided that such investigation shall be reasonably related to the transactions contemplated hereby and shall not interfere unnecessarily with normal operations. No investigation by either party shall affect the ability of that party to rely on the representations and warranties of the other party.
related to this Agreement or any other transaction contemplated hereby; provided, that nothing in this Section 5.11 shall be deemed to prohibit any party from making any disclosure which its counsel deems necessary or advisable in order to satisfy such party's disclosure obligations imposed by Law.
incurred, including, without limitation, any costs, fees and expenses of accountants, attorneys or other representatives or consultants engaged by the GGC Shareholder Representative in the course of his/her performance hereunder. CytRx and GGC hereby waive any conflicts of interests that may arise with respect to the GGC Shareholder Representative's actions in his/her capacity as GGC Shareholder Representative.
the exercise of outstanding options and warrants to purchase CytRx Common Stock or (ii) issuable or issued as an award under any stock option plan or long-term incentive plan described in the CytRx Disclosure Letter, except pursuant to contractual rights that exist as of the date hereof with the holders of such stock options and warrants. From and after the Effective Time, CytRx shall, and shall use its best efforts to cause its employees, agents and representatives to, process expeditiously (i) exercises of options and warrants to purchase CytRx Common Stock and (ii) sales of and other transactions involving CytRx Common Stock.
ARTICLE VI
CONDITIONS PRECEDENT
which are de minimis in amount. At Closing, GGC shall deliver an officer's certificate certifying that the above is true as of the Closing Date.
(1) a legal opinion of outside counsel to GGC in substantially the form attached hereto as Exhibit 6.2(j)(2);
(2) a copy of the final CytRx Business Plan;
(3) the Closing Liabilities Certificate; and
(4) the Escrow Agreement executed by GGC and the GGC Shareholder Representative.
ARTICLE VII
TERMINATION
(a) by the mutual consent of CytRx and GGC in a written instrument, whether or not the Merger has been approved by the stockholders of CytRx or the GGC Shareholders;
(b) by CytRx on behalf of itself and Merger Sub, upon a material breach of any representation, warranty, covenant or agreement on the part of GGC set forth in this Agreement,
or if any representation or warranty of GGC shall have become untrue such that the conditions set forth in Section 6.2, would be incapable of being satisfied by July 31, 2002;
(c) by GGC, upon a material breach of any representation, warranty, covenant or agreement on the part of CytRx or Merger Sub set forth in this Agreement, or if any representation or warranty of CytRx or Merger Sub shall have become untrue such that the conditions set forth in Section 6.3 would be incapable of being satisfied by July 31, 2002;
(d) by either CytRx or GGC, if (i) any Consent of any Regulatory Authority required for the consummation of the Merger and the other transactions contemplated hereby shall have been denied by final nonappealable action of such authority or if any action taken by such authority is not appealed within the time limit for appeal, or (ii) any injunction or action by any Regulatory Authority permanently restraining, enjoining or otherwise preventing the consummation of the Merger shall have become final and nonappealable;
(e) by either CytRx or GGC if the Merger shall not have been consummated on or prior to July 31, 2002 (or such later date as may be agreed to in writing by GGC and CytRx) (other than due to the failure of the party seeking to terminate this Agreement to perform its obligations under this Agreement required to be performed at or prior to the Effective Time);
(f) by either CytRx or GGC, if any approval of the stockholders of CytRx required for the consummation of the Merger shall not have been obtained by reason of the failure to obtain the required vote at the CytRx Stockholders' Meeting or at any adjournment thereof.
ARTICLE VIII
SURVIVAL; INDEMNIFICATION
(b) Any right of a Party to bring a claim against another Party hereto based on fraud in connection with this Agreement or the transactions contemplated hereby must be brought on or before the second annual anniversary of the Effective Time, or such claim shall be deemed to have expired and be forever waived by the Party alleging such fraud.
(a) After the Effective Time and until the applicable Indemnification Expiration Date, CytRx or the CytRx Representative, on behalf of CytRx, may deliver an Indemnification Claim to the GGC Shareholder Representative on behalf of GGC and the GGC Escrowees for all Damages asserted against, imposed upon or incurred by CytRx by reason of or resulting from (i) a breach of any representation, warranty, covenant or agreement of GGC contained in this Agreement or any certificate delivered pursuant hereto or (ii) the termination by GGC of the GGC Stock Options as contemplated by Section 2.4.
(b) After the Effective Time and until the applicable Indemnification Expiration Date, the GGC Shareholder Representative on behalf of GGC and the GGC Escrowees may deliver an Indemnification Claim to CytRx and the CytRx Representative on behalf of CytRx for all Damages asserted against, imposed upon or incurred by GGC by reason of or resulting from a breach of any representation, warranty, covenant or agreement of CytRx contained in this Agreement or any certificate delivered pursuant hereto.
(b) Upon receipt of any Third Party Claim Notice from the Indemnified Party, (i) the CytRx Representative, on behalf of CytRx, or (ii) the GGC Shareholder Representative, on behalf of GGC and the GGC Escrowees, as the case may be, may (unless the anticipated
Damages exceed the maximum amount of indemnification under Section 8.4) undertake the defense, compromise and settlement thereof by representatives of its own choosing reasonably acceptable to the Indemnified Party, the expenses, fees and costs of which shall be added to the Damages amount included in the Recoverable Amount pursuant to Section 8.5 of (i) GGC if the CytRx Representative undertakes such defense or (ii) CytRx if the GGC Shareholder Representative undertakes such defense. The assumption of the defense, compromise and settlement of any such Third Party Claim by a Representative will not be an acknowledgment by an Indemnifying Party of the obligation to indemnify the Indemnified Party with respect to such claim. If, however, a Representative fails or refuses to undertake the defense of such Third Party Claim within ten business days after notice of such Third Party Claim has been given to the Representative, the Indemnified Party will have the right to undertake the defense, compromise and settlement of such claim with counsel of its own choosing. If an Indemnifying Party undertakes the defense of a Third Party Claim and if in the reasonable opinion of counsel to the Indemnified Party there may exist defenses available to the Indemnified Party that are different from or in addition to those available to the Indemnifying Party or if the Indemnified Party otherwise believes that its interests would be adversely affected by the Indemnifying Party assuming sole control of the defense of such Third Party Claim, the Indemnified Party shall be entitled to retain separate counsel to participate in the defense of such Third Party Claim at its sole expense.
(c) No settlement of a Third Party Claim involving the asserted liability of the Indemnifying Party under this Section shall be made without the prior written consent by the respective Representative on behalf of such the Indemnifying Party. If the Indemnifying Party assumes the defense of a Third Party Claim, (i) no compromise or settlement thereof may be effected by the Indemnifying Party without the Indemnified Party's prior written consent unless (A) there is no finding or admission of any violation of law by or on behalf of the Indemnified Party, (B) the sole relief provided is monetary damages that are paid in full by the Indemnifying Party and (C) the compromise or settlement includes, as an unconditional term thereof, the giving by the claimant or the plaintiff to the Indemnified Party of a release, in form and substance reasonably satisfactory to the Indemnified Party, from all liability in respect of such Third Party Claim, and (ii) the Indemnified Party shall have no liability with respect to any compromise or settlement thereof affected without its consent.
(d) Each Party will provide the other Party with access to all records, documents and personnel of such Party to the extent reasonably related to any Third Party Claim.
(a) No Indemnification Claim may be made by any Party unless the aggregate amount of Damages indemnified against hereunder exceeds $25,000 in the aggregate, after which the Party may make an Indemnification Claim for the entire amount of Damages (including the first $25,000).
(b) In no event may the CytRx Representative on behalf of CytRx recover Damages under this Article VIII in excess of the Secondary Merger Consideration.
(c) In no event may the GGC Shareholder Representative on behalf of GGC and the GGC Escrowees recover Damages under this Article VIII in excess of the number of shares of CytRx Common Stock comprising the Secondary Merger Consideration at the Effective Time.
(a) All Damages recovered under this Article VIII shall be recovered in shares of CytRx Common Stock as set forth below. Although Indemnification Claims may be delivered at any time prior to the applicable Indemnification Expiration Date (subject to Section 8.4 above), no recovery of Damages shall be made by either party hereto until the first business day after the first anniversary date of the Effective Time (the "Recovery Date"). Upon the Recovery Date, or if any Indemnification Claim is still pending on the Recovery Date, on the first business day after final resolution of all pending Indemnification Claim(s), the parties shall add the aggregate amount of Damages recoverable by each party pursuant to Indemnification Claims properly made and resolved under this Article VIII (each a "Recoverable Amount"). The Party with the greater Recoverable Amount shall be entitled to recover an amount equal to the excess of such Party's Recoverable Amount minus the other Party's Recoverable Amount (the "Final Recoverable Amount").
(b) If CytRx has a greater Recoverable Amount on the Recovery Date, CytRx shall, in accordance with the Escrow Agreement, cancel a number of shares of CytRx Common Stock included in the Secondary Merger Consideration that when multiplied by the Average Closing Price equals the Final Recoverable Amount. For purposes of this Section 8.5(b), all fractional shares shall be rounded up to the nearest whole share. The remaining shares of CytRx Common Stock included in the Secondary Merger Consideration held in escrow, if any, shall be distributed to the GGC Escrowees in accordance with the Escrow Agreement.
(a) CytRx and the CytRx Representative are entitled to rely upon all actions taken and documents provided by the GGC Shareholder Representative as the actions of GGC and the GGC Escrowees and neither CytRx nor the CytRx Representative shall have any liability or obligation to GGC or the GGC Escrowees other than as provided in this Article VIII.
(b) GGC and the GGC Shareholder Representative are entitled to rely upon all actions taken and documents provided by the CytRx Representative as the actions of CytRx and neither GGC nor the GGC Shareholder Representative shall have any liability or obligation to CytRx other than as provided in this Article VIII.
ARTICLE IX
GENERAL PROVISIONS
(a) if to CytRx or Merger Sub, to:
CytRx Corporation
154 Technology Parkway
Suite 200
Norcross, Georgia 30092
Attention: Chief Executive Officer
Facsimile: (770) 368-0622
With a copy to:
Alston & Bird LLP
One Atlantic Center
1201 West Peachtree Street
Atlanta, Georgia 30309
Attention: Steven L. Pottle
Facsimile: (404) 881-7777
(b) if to the CytRx Representative, to:
Jack J. Luchese
3915 River Hollow Run
Duluth, Georgia 30092
With a copy to:
Alston & Bird LLP
One Atlantic Center
1201 West Peachtree Street
Atlanta, Georgia 30309
Attention: Steven L. Pottle
Facsimile: (404) 881-7777
(c) if to GGC, to:
GGC
11726 San Vicente Boulevard
Suite 650
Los Angeles, California 90049
Attention: ____________
Facsimile: (310) 826-5529
With a copy to:
Wasserman, Comden, Casselman & Pearson LLP
11755 Wilshire Boulevard
Suite 1230
Los Angeles, California 90025
Attention: Jeffrey L. Davidson and/or Clifford Pearson
Facsimile: (310) 473-0158
(d) if to the GGC Shareholder Representative, to:
Steven A. Kriegsman
c/o Kriegsman Capital Group LLC
11726 San Vicente Blvd., Suite 650
Los Angeles, California 90049
Facsimile: (310) 826-5529
With a copy to:
Wasserman, Comden, Casselman & Pearson LLP
11755 Wilshire Boulevard
Suite 1230
Los Angeles, California 90025
Attention: Jeffrey L. Davidson and/or Clifford Pearson
Facsimile: (310) 473-0158
(a) For purposes of this Agreement:
"Affiliate" of a Person means: (i) any other Person directly, or indirectly through one or more intermediaries, controlling, controlled by or under common control with such Person; (ii) any officer, director, partner, employer, or direct or indirect beneficial owner of any 10% or greater equity or voting interest of such Person; or (iii) any other Person for which a Person described in clause (ii) acts in any such capacity.
"Assets" of a Person means all of the assets, properties, businesses and rights of such Person of every kind, nature, character and description, whether real, personal or mixed, tangible or intangible, accrued or contingent, or otherwise relating to or utilized in such Person's business, directly or indirectly, in whole or in part, whether or not carried on the books and records of such Person, and whether or not owned in the name of such Person or any Affiliate of such Person and wherever located.
"Blizzard" means Blizzard Genomics, Inc.
"Consent" means any consent, approval, authorization, clearance, exemption, waiver, or similar affirmation by any Person pursuant to any Contract, Law, Order, or Permit.
"Contract" means any written or oral agreement, arrangement, authorization, commitment, contract, indenture, instrument, lease, license, obligation, plan, practice, restriction, understanding, or undertaking of any kind or character, or other document to which any Person is a party or that is binding on any Person or its capital stock, Assets or business.
"CytRx Common Stock" means the $0.001 par value common stock of CytRx.
"CytRx Entities" means, collectively, CytRx and all CytRx Subsidiaries.
"CytRx Rights" means the Equity Rights issued pursuant to the CytRx Rights Agreement.
"CytRx Rights Agreement" means that certain Shareholder Protection Rights Agreement, dated April 16, 1997, between CytRx and American Stock Transfer and Trust Company as Rights Agent.
"Damages" means all past, present and future demands, claims, suits, actions or causes of action, assessments, losses, damages, liabilities, fines, judgments, costs and expenses, including interest, penalties and reasonable attorneys' and consultants' fees, disbursements and expenses.
"Default" means (i) any breach or violation of, default under,
contravention of, or conflict with, any Contract, Law, Order, or Permit, (ii)
any occurrence of any event that with the passage of time or the giving of
notice or both would constitute a breach or violation of, default under,
contravention of, or conflict with, any Contract, Law, Order, or Permit, or
(iii) any occurrence of any event that with or without the passage of time or
the giving of notice would give rise to a right of any Person to exercise any
remedy or obtain any relief under, terminate or revoke, suspend, cancel, or
modify or change the current terms of, or renegotiate, or to accelerate the
maturity or performance of, or to increase or impose any Liability under, any
Contract, Law, Order, or Permit, where, in any such event, such Default is
reasonably likely to have, individually or in the aggregate, a Material Adverse
Effect on GGC or CytRx, as applicable.
"Designated GGC Shareholders" means the following holders of
Shares, who in the aggregate own a majority of the voting interests of GGC:
Steven A. Kriegsman, Corporate Consulting International Group, Michael R.
Hayden, Clifford H. Pearson, Steve K. Wasserman, David B. Casselman, Leonard J.
Comden, Leonard Ruiz, Jr., Elliott J. Cody and Wasserman, Comden, Casselman &
Pearson LLP.
"DGCL" means the Delaware General Corporation Law.
"Employee Benefit Plan" means each pension, retirement, profit-sharing, deferred compensation, stock option, employee stock ownership, share purchase, severance pay, vacation, bonus, retention, change in control or other incentive plan, medical, vision, dental or other health plan, any life insurance plan, flexible spending account, cafeteria plan, vacation, holiday, disability or any other employee benefit plan or fringe benefit plan, including any "employee benefit plan," as that term is defined in Section 3(3) of ERISA and any other plan, fund, policy, program, practice, custom understanding or arrangement providing compensation or other benefits, whether or not such Employee Benefit Plan is or is intended to be (i) covered or qualified under the Code, ERISA or any other applicable Law, (ii) written or oral, (iii) funded or unfunded, (iv) actual or contingent or (v) arrived at through collective bargaining or otherwise.
"Environmental Laws" means all Laws relating to pollution or protection of human health or the environment (including ambient air, surface water, ground water, land surface, or subsurface strata) including the Comprehensive Environmental Response
Compensation and Liability Act, as amended, 42 U.S.C. 9601 et seq. ("CERCLA"), the Resource Conservation and Recovery Act, as amended, 42 U.S.C. 6901 et seq. ("RCRA"), and other Laws relating to emissions, discharges, releases, or threatened releases of any Hazardous Material, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport, or handling of any Hazardous Material.
"Equity Rights" means all arrangements, calls, commitments, Contracts, options, rights to subscribe to, scrip, understandings, warrants, or other binding obligations of any character whatsoever relating to, or securities or rights convertible into or exchangeable for, shares of the capital stock of a Person or by which a Person is or may be bound to issue additional shares of its capital stock or other Equity Rights.
"ERISA" means the Employee Retirement Income Security Act of 1974, as amended.
"ERISA Affiliate" means any entity which together with a GGC Entity would be treated as a single employer under Code Section 414.
"Exchange Act" means the Securities Exchange Act of 1934, as amended.
"GGC Entities" means, collectively, GGC, all GGC Subsidiaries and Blizzard.
"GGC Escrowees" means the holders of Shares who surrender Certificates for Shares in the Merger and receive Merger Consideration, but shall not include any holder of Shares who exercised his/her appraisal rights under the CCC and received consideration for his/her Dissenting Shares in accordance with the CCC.
"GGC Shareholders Meeting" means the meeting of the holders of the Shares that has been called by GGC to vote on whether to approve the Merger.
"Hazardous Material" means (i) any hazardous substance, hazardous material, hazardous waste, regulated substance, or toxic substance (as those terms are defined by any applicable Environmental Laws) and (ii) any chemicals, pollutants, contaminants, petroleum, petroleum products, or oil, asbestos-containing materials and any polychlorinated biphenyls.
"Intellectual Property" means copyrights, patents, trademarks, service marks, service names, trade names, domain names, together with all goodwill associated therewith, registrations and applications therefor, technology rights and licenses, computer software (including any source or object codes therefor or documentation relating thereto), trade secrets, franchises, know-how, inventions, and other intellectual property rights.
"Knowledge" as used with respect to any Party means the actual knowledge of such Party's chairman, president, chief financial officer, treasurer or any senior, executive or other vice president or any other executive officer of such party. In addition, with respect to GGC, "Knowledge" shall also include the actual knowledge of Steven A. Kriegsman, Elliott J. Cody and Leonard Ruiz, Jr.
"Law" means any code, law (including common law), ordinance, regulation, reporting or licensing requirement, rule, or statute applicable to a Person or its Assets, Liabilities, or business, including those promulgated, interpreted or enforced by any Regulatory Authority.
"Liability" means any direct or indirect, primary or secondary, liability, indebtedness, obligation, penalty, cost or expense (including costs of investigation, collection and defense), claim, deficiency, guaranty or endorsement of or by any Person (other than endorsements of notes, bills, checks, and drafts presented for collection or deposit in the ordinary course of business) of any type, whether accrued, absolute or contingent, liquidated or unliquidated, matured or unmatured, or otherwise.
"Lien" means any conditional sale agreement, default of title, easement, encroachment, encumbrance, hypothecation, infringement, lien, mortgage, pledge, reservation, restriction, security interest, title retention or other security arrangement, or any adverse right or interest, charge, or claim of any nature whatsoever of, on, or with respect to any property or property interest, other than (i) Liens for current property Taxes not yet due and payable, and (ii) Liens which do not materially impair the use of or title to the Assets subject to such Lien.
"Litigation" means any action, arbitration, cause of action, lawsuit, claim, complaint, criminal prosecution, governmental or other examination or investigation, audit (other than regular audits of financial statements by outside auditors), compliance review, inspection, hearing, administrative or other proceeding relating to or affecting a Party, its business, its records, its policies, its practices, its compliance with Law, its actions, its Assets (including Contracts related to it), or the transactions contemplated by this Agreement.
"Material" or "material" for purposes of this Agreement shall be determined in light of the facts and circumstances of the matter in question; provided that any specific monetary amount stated in this Agreement shall determine materiality in that instance.
"Material Adverse Effect" means:
(i) with respect to CytRx, an event, change or occurrence which, individually or together with any other event, change or occurrence, has a material adverse impact on (1) the financial position, business, or results of operations of CytRx and its Subsidiaries, taken as a whole, or (2) the ability of CytRx to perform its obligations under this Agreement or to consummate the Merger or the other transactions contemplated by this Agreement, provided that "Material Adverse Effect" with respect to CytRx shall not be deemed to include the impact of (A) changes in Laws of general applicability or interpretations thereof by courts or governmental authorities, (B) changes in generally accepted accounting principles, (C) actions and omissions of CytRx (or any of its Subsidiaries) taken with the prior informed written Consent of GGC in contemplation of the transactions contemplated hereby, (D) the direct effects of compliance with this Agreement on the operating performance of CytRx, including expenses incurred by CytRx in consummating the transactions contemplated by this Agreement, (E) effects demonstrably shown to have been proximately caused by the public announcement of, and the response or reaction of customers, vendors, licensors, licensees, investors or employees of CytRx to, this Agreement or any of the transactions contemplated by this Agreement, (F) failure of CytRx to meet the revenue or earnings predictions of equity analysts (as reflected in the First Call consensus estimate), or
any other published revenue or earnings predictions or expectations, for any period ending on or after the date of this Agreement, (G) changes in the market price or trading volume of CytRx Common Stock, or (H) delisting of CytRx Common Stock from the Nasdaq National Market; and
(ii) with respect to GGC, an event, change or occurrence which, individually or together with any other event, change or occurrence, has a material adverse impact on (1) the financial position, business, or results of operations of GGC and its Subsidiaries, taken as a whole, or (2) the ability of GGC to perform its obligations under this Agreement or to consummate the Merger or the other transactions contemplated by this Agreement, provided that "Material Adverse Effect" with respect to GGC shall not be deemed to include the impact of (A) changes in Laws of general applicability or interpretations thereof by courts or governmental authorities, (B) actions and omissions of GGC (or any of its Subsidiaries) taken with the prior informed written Consent of CytRx in contemplation of the transactions contemplated hereby, or (C) the direct effects of compliance with this Agreement on the operating performance of GGC, including expenses incurred by GGC in consummating the transactions contemplated by this Agreement.
"Operating Property" means any property owned, leased, or operated by the Party in question or by any of its Subsidiaries or in which such Party or Subsidiary holds a security interest or other interest (including an interest in a fiduciary capacity), and, where required by the context, includes the owner or operator of such property, but only with respect to such property.
"Order" means any administrative decision or award, decree, injunction, judgment, order, quasi-judicial decision or award, ruling, or writ of any federal, state, local or foreign or other court, arbitrator, mediator, tribunal, administrative agency, or Regulatory Authority.
"Party" means either any of GGC, Merger Sub or CytRx, and "Parties" means GGC, Merger Sub and CytRx. "Permit" means any federal, state, local, and foreign |
governmental approval, authorization, certificate, easement, filing, franchise, license, notice, permit, or right to which any Person is a party or that is or may be binding upon or inure to the benefit of any Person or its securities, Assets, or business.
"Person" means a natural person or any legal, commercial or Regulatory Authority, such as, but not limited to, a corporation, general partnership, joint venture, limited partnership, limited liability company, limited liability partnership, trust, business association, group acting in concert, or any person acting in a representative capacity
"Regulatory Authorities" means, collectively, the SEC, the Nasdaq National Market, and all other federal, state, county, local or other governmental or regulatory agencies, authorities (including taxing and self-regulatory authorities), instrumentalities, commissions, boards or bodies having jurisdiction over the Parties and their respective Subsidiaries.
"SEC" means the United States Securities and Exchange Commission.
"Securities Act" means the Securities Act of 1933, as amended.
"Securities Laws" means the Securities Act, the Exchange Act, the Investment Company Act of 1940, as amended, the Investment Advisors Act of 1940, as amended, the Trust Indenture Act of 1939, as amended, and the rules and regulations of any Regulatory Authority promulgated thereunder.
"Subsidiary" means all those corporations, associations, or other business entities of which the entity in question either (i) owns or controls 50% or more of the outstanding equity securities either directly or through an unbroken chain of entities as to each of which 50% or more of the outstanding equity securities is owned directly or indirectly by its parent (provided, there shall not be included any such entity the equity securities of which are owned or controlled in a fiduciary capacity), (ii) in the case of partnerships, serves as a general partner, (iii) in the case of a limited liability company, serves as a managing member, or (iv) otherwise has the ability to elect a majority of the directors, trustees or managing members thereof.
"Tax" or "Taxes" means any federal, state, county, local, or foreign taxes, charges, fees, levies, imposts, duties, or other assessments, including income, gross receipts, excise, employment, sales, use, transfer, recording license, payroll, franchise, severance, documentary, stamp, occupation, windfall profits, environmental, federal highway use, commercial rent, customs duties, capital stock, paid-up capital, profits, withholding, Social Security, single business and unemployment, disability, real property, personal property, registration, ad valorem, value added, alternative or add-on minimum, estimated, or other tax or governmental fee of any kind whatsoever, imposed or required to be withheld by the United States or any state, county, local or foreign government or subdivision or agency thereof, including any interest, penalties, and additions imposed thereon or with respect thereto.
"Tax Return" means any report, return, information return, or other information required to be supplied to a Regulatory Authority in connection with Taxes, including any return of an affiliated or combined or unitary group that includes a Party or its Subsidiaries.
(b) Any accounting term that is used in the context of describing or referring to an accounting concept and that is not specifically defined herein shall be construed in accordance with GAAP.
hereto or their respective successors, any rights, remedies, obligations or
liabilities under or by reason of this Agreement, other than (i) as provided in
Section 5.5 hereto, (ii) with respect to Eligible CytRx Directors regarding
Sections 5.12, 5.14, 9.12 and 9.13, (iii) with respect to the CytRx
Representative regarding Sections 5.14 and Article VIII and (iv) with respect to
the GGC Shareholder Representative regarding Sections 5.13 and Article VIII.
9.6 [INTENTIONALLY OMITTED]
provided, that after any such approval by the holders of CytRx Common Stock, the provisions of this Agreement relating to the manner or basis in which shares of GGC capital stock will be exchanged for shares of CytRx Common Stock shall not be amended after the CytRx Stockholders' Meeting in a manner adverse to the holders of CytRx Common Stock without any requisite approval of the holders of the issued and outstanding shares of CytRx Common Stock entitled to vote thereon. This Agreement may not be amended except by an instrument in writing signed on behalf of each of the Parties hereto. Notwithstanding any of the above, after the Effective Time, CytRx may not amend this Agreement (including this provision) or take any actions inconsistent with this Agreement, unless a majority of the Eligible CytRx Directors then serving on the CytRx board of directors approves in advance of such amendment or action.
IN WITNESS WHEREOF, CytRx, Merger Sub and GGC have caused this Agreement, to be signed by their respective officers thereunto duly authorized, all as of the date first written above.
CYTRX CORPORATION GLOBAL GENOMICS CAPITAL, INC.
By: /s/ Jack J. Luchese By: /s/ Steven A. Kriegsman ------------------------ --------------------------------- Name: Jack J. Luchese Name: Steven A. Kriegsman ---------------------- ------------------------------- |
Title: President & CEO Title: Chairman --------------------- ------------------------------ GGC MERGER CORPORATION By: /s/ Jack J. Luchese ------------------------ |
Name: Jack J. Luchese ---------------------- Title: President & CEO --------------------- |
Exhibit 4.2
CYTRX CORPORATION
154 Technology Parkway
Norcross, Georgia 30092
February 11, 2002
American Stock Transfer & Trust Company
40 Wall Street
New York, New York 10005
Attention: Corporate Trust Department
Re: Amendment No. 1 to Shareholder Protection Rights Agreement dated as of April 16, 1997 (the "Rights Agreement") between CytRx Corporation
("CytRx") and American Stock Transfer & Trust Company ("AST")
Ladies and Gentlemen:
Pursuant to Section 5.4 of the Rights Agreement, CytRx, by resolution adopted by its board of directors, hereby amends the Rights Agreement as follows:
1. The definition of "Acquiring Person" in Section 1.1 of the Rights Agreement is hereby deleted and replaced in its entirety with the following:
"Acquiring Person" shall mean any Person who is a Beneficial Owner of 15% or more of the outstanding shares of Common Stock; provided, however, that the term "Acquiring Person" shall not include any Person (i) who is the Beneficial Owner of 15% or more of the outstanding shares of Common Stock on the date of this Agreement or who shall become the Beneficial Owner of 15% or more of the outstanding shares of Common Stock solely as a result of an acquisition by the Company of shares of Common Stock, until such time hereafter or thereafter as any of such Persons shall become the Beneficial Owner (other than by means of stock dividend or stock split) of any additional shares of Common Stock, (ii) who, on or after the date of this Agreement, is or shall become the Beneficial Owner of 15% or more of the outstanding shares of Common Stock (or securities convertible into, exchangeable into or exercisable for Common Stock) pursuant to the Agreement and Plan of Merger dated as of February 11, 2002 (the "Merger Agreement") among the Company, Global Genomics Capital, Inc. and GGC Merger Corporation or the Merger (as defined in the Merger Agreement or other transactions contemplated by the Merger Agreement, until such time hereafter or thereafter as such Person shall become the Beneficial Owner (other than (1) by means of a stock dividend, stock split or other similar event or (2) pursuant to the exercise of any stock option granted by the Company's board of directors or compensation committee on or after the date of this Agreement to such Person in such Person's capacity as an officer or
director of the Company) of any additional shares of Common Stock, (iii) who is the Beneficial Owner of 15% or more of the outstanding shares of Common Stock but who acquired Beneficial Ownership of shares of Common Stock without any plan or intention to seek or affect control of the Company, if such Person promptly enters into an irrevocable commitment promptly to divest, and thereafter promptly divests (without exercising or retaining any power, including voting power, with respect to such shares), sufficient shares of Common Stock (or securities convertible into, exchangeable into or exercisable for Common Stock) so that such Person ceases to be the Beneficial Owner of 15% or more of the outstanding shares of Common Stock or (iv) who Beneficially Owns shares of Common Stock consisting solely of one or more of (A) shares of Common Stock Beneficially Owned pursuant to the grant or exercise of an option granted to such Person by the Company in connection with an agreement to merge with, or acquire, the Company entered into prior to a Flip-In Date, (B) shares of Common Stock (or securities convertible into, exchangeable into or exercisable for Common Stock) acquired by Affiliates or Associates of such Person after the time of such grant which, in the aggregate, amount to less than 1% of the outstanding shares of Common Stock. In addition, the Company, any wholly owned Subsidiary of the Company and any employee stock ownership or other employee benefit plan of the Company or a wholly owned Subsidiary of the Company shall not be an Acquiring Person.
2. The definition of "Stock Acquisition Date" in Section 1.1 of the Rights Agreement is hereby amended by adding the following sentence to the end thereof:
"Neither the Merger Agreement nor the Merger or any other transaction contemplated thereby shall cause a Stock Acquisition Date."
3. The definition of "Separation Time" in Section 1.1 of the Rights Agreement is hereby amended by adding the following sentence to the end thereof:
"Neither the Merger Agreement nor the Merger or any other transaction contemplated thereby shall cause a Separation Time."
4. Section 5.4 of the Rights Agreement is hereby amended by adding the following sentence to the end thereof:
"Notwithstanding the above, from the Effective Time (as defined in the Merger Agreement) until the second anniversary thereof, no amendment or supplement may be made to this Agreement, and no such amendment or supplement shall be effective, without the prior approval of a majority of the then-disinterested members of the Company's board of directors."
5. Except as expressly amended hereby, the Rights Agreement shall remain in full force and effect.
6. Capitalized terms used herein and not otherwise defined herein shall have the meaning ascribed to them in the Rights Agreement.
7. This Amendment No. 1 shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to the conflicts of law principles thereof.
8. This Amendment No. 1 may be executed in any number of counterparts and each of such counterparts shall be deemed to be an original and all of which together shall be deemed to be one and the same agreement.
9. This Amendment No. 1 to the Rights Agreement shall be effective as of the date hereof, and all references to the Rights Agreement shall, from and after such time, be deemed to be references to the Rights Agreement as amended hereby.
Very truly yours,
CytRx Corporation
By: /s/ Jack J. Luchese ---------------------- Name: Jack J. Luchese --------------------- Title: President & CEO -------------------- |
Accepted and agreed to as of the date first written above:
American Stock Transfer & Trust Company
By: /s/ Herbert J. Lemmer -------------------------- Name: Herbert J. Lemmer ------------------------ Title: Vice President ----------------------- |
Exhibit 10.4
AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT
with Jack J. Luchese
This AMENDMENT No. 1 (the "Amendment"), effective as of January 1, 2002, by and between CytRx Corporation, a Delaware corporation (the "Company"), and Jack J. Luchese ("Mr. Luchese"), amends that certain Amended and Restated Employment Agreement, dated as of September 1, 1999, by and between the Company and Mr. Luchese (the "Employment Agreement").
In consideration of the mutual promises and covenants herein contained, the parties hereto agree as follows:
1. The caption of Section 3 of the Employment Agreement is hereby renamed "Compensation" and new subsections 3(c), 3(d) and 3(e) of the Employment Agreement are hereby added, to read as follows:
within thirty (30) days of a final determination of his liability therefor as
set forth below, the Success Bonus (as defined in Section 3(c) above) and the
Change in Control Payment (as defined in Section 3(d) above) if at any time
during the period of two years after the termination of his employment (the
"Restricted Period") he violates the restrictions on competition set forth in
Section 10 hereof. Any determination of whether Mr. Luchese has violated such
non-competition restrictions shall be made by arbitration in Atlanta, Georgia
under the Rules of Commercial Arbitration (the "Rules") of the American
Arbitration Association, which Rules are deemed to be incorporated by reference
herein."
2. A new subsections 7(d) of the Employment Agreement is hereby added, to read as follows:
3. As amended hereby, the Employment Agreement shall be and remain in full force and effect.
IN WITNESS WHEREOF, Mr. Luchese has hereunto set his hand and, pursuant to the authorization from its Board of Directors, the Company has caused this Agreement to be executed in its name on its behalf by its undersigned officer thereunto, duly authorized, all as of the day and year first above written.
/s/ Jack J. Luchese --------------------------------- Jack J. Luchese Attest: CYTRX CORPORATION: /s/ Mark W. Reynolds /s/ William B. Fleck --------------------- ----------------------------------- Corporate Secretary By: William B. Fleck (CORPORATE SEAL) Title: Vice President, Human Resources /s/ Herbert H. McDade, Jr. ------------------------------------ By: Herbert H. McDade, Jr. Title: Chairman, CytRx Compensation Committee |
Exhibit 10.6
AMENDMENT NO. 1 TO CHANGE IN CONTROL EMPLOYMENT AGREEMENT
with Jack J. Luchese
This AMENDMENT No. 1(the "Amendment"), effective as of January 1, 2002, by and between CytRx Corporation, a Delaware corporation (the "Company"), and Jack J. Luchese ("Executive"), amends that certain Amended and Restated Change in Control Employment Agreement, dated as of September 1, 1999, by and between the Company and Executive (the "Change in Control Agreement").
In consideration of the mutual promises and covenants herein contained, the parties hereto agree as follows:
1. The Change in Control Agreement is hereby amended by deleting subsection 2(c) thereof and substituting the following therefor:
"(c) Consummation of a reorganization, merger or consolidation or sale or other disposition of all or substantially all of the assets of the Company (a "Business Combination"), in each case, unless, following such Business Combination, (i) all or substantially all of the individuals and entities who were the beneficial owners, respectively, of the Outstanding Company Common Stock and outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 70% of, respectively, the then outstanding shares of common stock and the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors, as the case may be, of the corporation resulting from such Business Combination (including, without limitation, a corporation which as a result of such transaction owns the Company or all or substantially all of the Company's assets either directly or through one or more subsidiaries) in substantially the same proportions as their ownership, immediately prior to such Business Combination of the Outstanding Company Common Stock and Outstanding Company Voting Securities, as the case may be, (ii) no Person (excluding any corporation resulting from such Business Combination or any employee benefit plan (or related trust) of the Company or such corporation resulting from such Business Combination) beneficially owns, directly or indirectly, 25% or more of the combined voting power of the then outstanding voting securities of such corporation except to the extent that such ownership existed prior to the Business Combination, and (iii) at least a majority of the members of the board of directors of the corporation resulting from such Business Combination were members of the Incumbent Board at the time of the execution of the initial agreement, or of the action of the Board, providing for such Business Combination; or".
2. A new subsection 4(b)(vii) of the Change in Control Agreement is hereby added, to read as follows:
such event being referred to as a "Milestone Event"), the Company shall pay to the Executive a success bonus equal to $435,150 (the "Success Bonus", less the amount, if any, of any success bonus for a Milestone Event previously paid to the Executive under Section 3(c) of the Employment Agreement). The Success Bonus shall be paid in a lump sum in cash as soon as practicable after the occurrence of the applicable Milestone Event. The Success Bonus is subject to forfeiture as provided in Section 6(a)(iv) below."
3. A new subsection 4(b)(viii) of the Change in Control Agreement is hereby added, to read as follows:
4. The Change in Control Agreement is hereby amended by deleting subsection 6(a)
(i)(B) thereof and substituting the following therefor:
"B. to the extent earned and not theretofore paid, the Success Bonus (as defined in Section 4(b)(vii) above) and the Change in Control Payment (as defined in Section 4(b)(viii) above); and"
5. The Change in Control Agreement is hereby amended by deleting subsection 6(a)
(iv) thereof and substituting the following therefor:
"(iv) Notwithstanding any provision of this Agreement to the contrary, the Executive shall forfeit his right to receive, or, to the extent such amounts have previously been paid to the Executive, shall repay in full to the Company with interest at 8% per annum within thirty (30) days of a final determination of the Executive's liability therefor as set forth below, the Success Bonus (as defined in Section 4(b)(vii) above) and the Change in Control Payment (as defined in Section 4(b)(viii) above) if at any time during the period of two years after the Date of Termination (the "Restricted Period") he violates the restrictions on competition set forth in Section 11 hereof. Any determination of whether the Executive has violated such non-competition restrictions shall be made by arbitration in Atlanta, Georgia under the Rules of Commercial Arbitration (the "Rules") of the American Arbitration Association, which Rules are deemed to be incorporated by reference herein."
6. As amended hereby, the Change in Control Agreement shall be and remain in full force and effect.
IN WITNESS WHEREOF, the Executive has hereunto set the Executive's hand and, pursuant to the authorization from its Board of Directors, the Company has caused this Agreement to be executed in its name on its behalf by its undersigned officer thereunto, duly authorized, all as of the day and year first above written.
/s/ Jack J. Luchese -------------------------------------------- Jack J. Luchese Attest: CYTRX CORPORATION: /s/ Mark W. Reynolds /s/ William B. Fleck --------------------- -------------------------------------------- Corporate Secretary By: William B. Fleck (CORPORATE SEAL) Title: Vice President, Human Resources /s/ Herbert H. McDade, Jr. ------------------------------------ By: Herbert H. McDade, Jr. Title: Chairman, CytRx Compensation Committee |
Exhibit 10.12
Amendment No. 1 to the
CytRx Corporation 2000 Long-Term Incentive Plan
This Amendment No. 1 ("Amendment") to the CytRx Corporation 2000 Long-Term Incentive Plan (the "Plan") is made and executed this 8th day of February, 2002, to be subject to, and effective as of the date of, stockholder approval of this Amendment.
WHEREAS, the Board of Directors of CytRx Corpration (the "Company") has determined that it would be desirable and in the best interests of the Company and its stockholders to amend the Plan to increase by 2,000,000 the number of shares available for issuance thereunder, which amendment requires stockholder approval; and
NOW, THEREFORE, in accordance with Section 15.1 of the Plan, the Plan is hereby amended as follows:
1. Authorized Shares. The number "1,000,000" in the first sentence of Section 5.1 of the Plan is hereby deleted and replaced with the number "3,000,000."
2. Effect of Amendment. As modified hereby, the provisions of the Plan shall remain in full force and effect, and the Plan may be restated, as amended hereby, in its entirety.
IN WITNESS WHEREOF, the Company has caused this Amendment to be duly executed as of the date first above written.
CytRx Corporation
By: /s/ Mark W. Reynolds ----------------------------------------------- Name: Mark W. Reynolds -------------------------------------- Title: Vice President, Finance and Secretary -------------------------------------- |
Exhibit 10.13
Amendment No. 2 to the
CytRx Corporation 2000 Long-Term Incentive Plan
This Amendment No. 2 ("Amendment") to the CytRx Corporation 2000 Long-Term Incentive Plan (the "Plan") is made, executed and effective as of this 1st day of March, 2002.
WHEREAS, CytRx Corporation (the "Company"), GGC Merger Corporation ("Merger Sub") and Global Genomics Capital, Inc. ("GGC") are parties to an Agreement and Plan of Merger dated as of February 11, 2002 (the "Merger Agreement"), under which Merger Sub will merge with and into GGC (the "Merger");
WHEREAS, the signing of the Merger Agreement and the consummation of the Merger will trigger certain cash payments (the "Cash Payments") from the Company to its executive officers under employment and other agreements between each executive officer of the Company and the Company;
WHEREAS, the Board of Directors of the Company previously determined that it is in the best interests of the Company for the Company to offer to grant stock awards to the executive officers under the Plan (the "Stock Awards") in lieu of paying, partially or in full, the Cash Payments;
WHEREAS, the Plan contained certain limitations that would prohibit the Company from granting the Stock Awards; and
WHEREAS, the Compensation Committee of the Company has determined that it would be desirable and in the best interests of the Company and its stockholders to amend the Plan to remove or increase such limitations to effectuate the granting of the Stock Awards.
NOW, THEREFORE, in accordance with Section 15.1 of the Plan, the Plan is hereby amended as follows:
1. The text of Section 5.1 of the Plan is hereby deleted in its entirety and replaced with the following:
"Subject to adjustment as provided in Section 14.1, the aggregate number of shares of Stock reserved and available for Awards or which may be used to provide a basis of measurement for or to determine the value of an Award (such as with a Stock Appreciation Right or Performance Unit Award) shall be 3,000,000."
2. The text of Section 5.4 of the Plan is amended by deleting each reference to "200,000" and replacing it with "500,000" and by deleting "$500,000" and replacing it with "1,000,000".
3. As modified hereby, the provisions of the Plan shall remain in full force and effect, and the Plan may be restated, as amended hereby, in its entirety.
IN WITNESS WHEREOF, the Company has caused this Amendment to be duly executed as of the date first above written.
CytRx Corporation
By: /s/ Mark W. Reynolds -------------------------------------------- Name: Mark W. Reynolds ------------------------------------- Title: Vice President, Finance and Secretary -------------------------------------- |
Exhibit 21.1
CYTRX CORPORATION
2001 FORM 10-K
SUBSIDIARIES OF THE REGISTRANT
Name of Subsidiary State of Incorporation Percentage of Ownership ------------------ ---------------------- ----------------------- GGC Merger Corporation California 100% |
Exhibit 23.1
CONSENT OF INDEPENDENT AUDITORS
We consent to the incorporation by reference in the Registration Statements on Form S-8 No. 33-42259 pertaining to the CytRx Corporation 1986 Stock Option Plan, No. 33-93816 pertaining to the CytRx Corporation 1994 Stock Option Plan, No. 33-93818 pertaining to the CytRx Corporation 1995 Stock Option Plan, No. 333-84657 pertaining to the CytRx Corporation 1998 Long Term Incentive Plan and No. 333-68200 pertaining to the CytRx Corporation 2000 Long Term Incentive Plan and to the Registration Statements on Form S-3 Nos. 33-93820, 333-39607, 333-44043, 333-48837, 333-45652, 333-33792 and 333-68092 of CytRx Corporation and in the related prospectuses of our report dated March 1, 2002, with respect to the consolidated financial statements and schedule of CytRx Corporation included in this Annual Report (Form 10-K) for the year ended December 31, 2001.
/s/ Ernst & Young LLP Atlanta, Georgia March 26, 2002 |